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ABSTRACT: Leber Congenital Amaurosis (LCA), the most severe inherited retinal dystrophy, is 
genetically heterogeneous, with 14 genes accounting for 70% of patients. Here, 91 LCA probands 
underwent LCA chip analysis and subsequent sequencing of 6 genes (CEP290, CRB1, RPE65, 
GUCY2D, AIPL1 and CRX), revealing mutations in 69% of the cohort, with major involvement of 
CEP290 (30%). In addition, 11 patients with early-onset retinal dystrophy (EORD) and 13 patients 
with Senior-Loken syndrome (SLS), LCA-Joubert syndrome (LCA-JS) or cerebello-oculo-renal 
syndrome (CORS) were included. Exhaustive re-inspection of the overall phenotypes in our LCA 
cohort revealed novel insights mainly regarding the CEP290-related phenotype. The AHI1 gene 
was screened as a candidate modifier gene in three patients with the same CEP290 genotype but 
different neurological involvement. Interestingly, a heterozygous novel AHI1 mutation, 
p.Asn811Lys, was found in the most severely affected patient. Moreover, AHI1 screening in five 
other patients with CEP290-related disease and neurological involvement revealed a second novel 
missense variant, p.His758Pro, in one LCA patient with mild mental retardation and autism. These 
two AHI1 mutations might thus represent neurological modifiers of CEP290-related disease. ©2010 
Wiley-Liss, Inc. 
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INTRODUCTION 
Leber Congenital Amaurosis (LCA; MIM# 204000) was first described as a congenital type of retinitis 
pigmentosa (RP). Approximately 20% of all blind children are thought to suffer from this disease. Phenotypic 
features include a congenital onset, severely reduced or absent electroretinogram (ERG), nystagmus, the oculo-
digital sign and a fundus aspect varying from normal to severely atrophic. Two main types of LCA have been 
reported, based on the presence or absence of photophobia, night blindness, hyperopia, macular/peripheral retinal 
abnormalities and measurable visual acuity (Hanein et al., 2004; Hanein et al., 2006). LCA displays variable 
expression, and seems to represent the extreme and severe end of a spectrum of inherited retinal disease. 
LCA is predominantly inherited in an autosomal recessive manner. So far, one locus - LCA9 (Keen et al., 2003) 
- and the following 14 genes have been identified: GUCY2D (Perrault et al., 1996), RPE65 (Marlhens et al., 1997), 
CRX (Freund et al., 1998), AIPL1 (Sohocki et al., 2000a), RPGRIP1 (Dryja et al., 2001), CRB1 (den Hollander et 
al., 2001), RDH12 (Perrault et al., 2004), IMPDH1 (Bowne et al., 2006), CEP290 (den Hollander et al., 2006), 
RD3 (Friedman et al., 2006), LCA5 (den Hollander et al., 2007) and SPATA7 (Wang et al., 2009), with the 
involvement of TULP1 (Hagstrom et al., 1998) and LRAT (Thompson et al., 2001) under debate. Mutations in 
these genes account for ~70% of all LCA cases. Several of them are also implicated in other retinal dystrophies: 
CRB1, RPE65, RDH12 and SPATA7 are associated with both LCA and early-onset retinal dystrophy (EORD), 
which often overlap (Gu et al., 1997; den Hollander et al., 1999; Janecke et al., 2004; Wang et al., 2009). 
Several subtypes of LCA can be considered part of the ciliopathies, as four disease genes – TULP1, RPGRIP1, 
CEP290 and LCA5 – encode ciliary proteins. Since cilia are present throughout the whole body, mutations in 
ciliary genes may cause a broad phenotypic spectrum. One of the best examples is CEP290, the most frequently 
mutated gene in the western European LCA population. In addition to LCA, CEP290 is associated with Joubert 
syndrome (JS; MIM# 213300), Senior-Loken syndrome (SLS; MIM# 266900), Meckel-Grüber syndrome (MKS; 
MIM# 249000) and Bardet-Biedl syndrome (BBS; MIM# 209900); a range of clinically and genetically 
heterogeneous ciliopathies (Sayer et al., 2006; Valente et al., 2006b; Baala et al., 2007; Brancati et al., 2007; Helou 
et al., 2007; Leitch et al., 2008). Recent studies suggest that modifiers may play a role in the pathogenesis of 
ciliopathies (Leitch et al., 2008; Khanna et al., 2009; Louie et al., 2010).  
Establishing a molecular diagnosis for LCA is not only important in the context of genetic counselling and 
clinical prognosis, but is also essential in view of future gene therapy. Recent Phase I clinical trials for RPE65 
gene replacement therapy provide hopeful prospects for the treatment of inherited retinal dystrophies (Bainbridge 
et al., 2008; Hauswirth et al., 2008; Maguire et al., 2008; Cideciyan et al., 2009; Maguire et al., 2009). As such 
therapies are likely to be gene-specific, the development of robust clinical testing and efforts toward gene 
identification are of utmost importance.  
Current diagnostic testing for LCA generally involves chip analysis that contains known mutations in all known 
LCA and EORD genes (Asper Ophthalmics, Estonia). Depending on the population, causal mutations are found in 
approximately 55% of all cases (Yzer et al., 2006). Only a limited number of laboratories subsequently screen an 
additional number of genes (Stone, 2007; den Hollander et al., 2008). 
This study includes an extensive genetic survey in order to identify the molecular cause in 91 LCA probands 
mainly of Belgian origin, using LCA chip analysis for 8 to 13 genes and subsequent sequencing of the following 
genes: CEP290 (MIM# 610142), CRB1 (MIM# 604210), RPE65 (MIM# 180069), GUCY2D (MIM# 600179), 
AIPL1 (MIM# 604392) and CRX (MIM# 602225). In addition, exhaustive phenotyping was performed in all 
patients carrying mutation(s), and the AHI1 gene was screened for modifier alleles of CEP290-related disease. 
MATERIALS AND METHODS 
Patients 
Ninety-one consenting subjects initially diagnosed with LCA were referred for molecular testing by an 
ophthalmologist and/or geneticist, mainly associated with the University Hospitals of Ghent, Leuven or Brussels. 
Eleven probands are born from a consanguineous marriage. The inclusion criteria for LCA were bilateral visual 
loss before the age of 6 months accompanied by nystagmus and an undetectable or significantly reduced ERG. 
Twelve patients presented with additional mental retardation and/or autistic behaviour. For 18 patients with an 
available Magnetic Resonance Imaging (MRI), the absence of a molar tooth sign (MTS) excluded the diagnosis of Genetic Screening of LCA in Belgium  E1711 
 
JS. In addition, genotyping was performed on 11 probands with EORD (disease diagnosed beyond the first six 
months of life but before the age of three) and 13 with a retinal dystrophy in the context of JS (LCA-JS), SLS or 
cerebello-oculo-renal syndrome (CORS). These patients were not included during calculations of gene-specific 
contributions in isolated LCA. Genomic DNA and RNA were extracted from leukocytes using the Puregene DNA 
isolation kit (Gentra) and the RNeasy Mini kit (Qiagen) respectively, followed by cDNA synthesis with the iScript 
cDNA Synthesis kit (Bio-Rad). If available, parents and/or siblings were also genotyped. Seven of the patients 
were reported previously (Yzer et al., 2006; Brancati et al., 2007; Perrault et al., 2007). Patient notation was 
performed according to their clinical diagnosis (prefixes LCA, SLS, LCA-JS, CORS and EORD), with consecutive 
numbering in the order of the genes involved. 
Genotyping 
As a pre-screening method, all patients with either isolated LCA or EORD were analysed with a microarray 
containing 344 to 641 mutations in 8 (GUCY2D, CRX, RPE65, CRB1, RPGRIP1, AIPL1, LRAT and MERTK) to 13 
(addition of TULP1, LCA5, RDH12, CEP290 and SPATA7) LCA and EORD genes (LCA chip Versions 2004-
2009; Asper Ophthalmics, Estonia) (http://www.asperbio.com) (Zernant et al., 2005). Each of the mutations found 
by the LCA chip was subsequently confirmed through Sanger sequencing. In case of a heterozygous mutation, the 
coding exons and intron-exon boundaries of the involved gene were sequenced.  
Patients in whom no mutations were identified after LCA chip analysis were analysed through sequencing of all 
coding exons and intron-exon boundaries of CEP290, CRB1, RPE65, GUCY2D, AIPL1 and CRX, the first five 
genes being the most frequently mutated in LCA. At the time the LCA chip did not yet include CEP290 variants, 
stepwise targeted mutation analysis was performed prior to sequencing of the total coding region. We initially 
screened for the frequent c.2991+1655A>G mutation followed by four additional mutations: c.4723A>T 
(p.Lys1575X), c.5587-1G>C (splice site), c.5163del (p.Thr1722GlnfsX2) and c.3310-1_3310delinsAA (splice 
site). The first three mutations occurred multiple times in a previous study (Perrault et al., 2007); the latter was 
found in three patients with a heterozygous c.2991+1655A>G mutation in our population. CEP290 was also 
screened at cDNA level in patients with only a single mutation in CEP290. To this end, cDNA screening using 16 
overlapping primer sets was optimized. Four patients with CEP290-related LCA who presented with mental 
retardation, two patients with SLS, one patient with CORS and one patient with LCA-JS underwent sequencing of 
the AHI1 gene. For 13 patients with SLS/LCA-JS/CORS, molecular testing of CEP290 was requested. Supp. Table 
S1 includes all primer sequences used in this study.  
Mutation nomenclature 
Mutation nomenclature uses numbering with the A of the initiation codon ATG as +1 
(www.hgvs.org/mutnomen), based on the following RefSeqs: NM_201253.1 (CRB1), NM_000329.2 (RPE65), 
NM_000180.3 (GUCY2D), NM_014336.3 (AIPL1), NM_000554.4 (CRX), NM_025114.3 (CEP290), 
NM_152443.2 (RDH12), NM_020366.3 (RPGRIP1) and NM_001134831.1 (AHI1) 
(http://www.ncbi.nlm.nih.gov/nuccore). All mutations and variants found in CEP290 were submitted to the locus-
specific mutation database CEP290base (http://medgen.ugent.be/cep290base) (Coppieters et al., 2010). 
Evaluation of sequence changes 
The presence of all mutations was confirmed on a second PCR product. Segregation analysis of disease alleles 
was performed if possible. Genomic DNA obtained from > 340 unrelated ethnically matched healthy individuals 
was used as a control panel. Thorough bio-informatic evaluation of novel variants was done using Alamut software 
(v.1.5). Variants were designated as “unclassified variant (UV)” if no consensus was seen in all prediction 
programs used. The Alamut output for missense changes is listed in Supp. Table S2. 
Clinical evaluation of patients 
After identification of the molecular cause, clinical records were revisited, based on a clinical checklist 
comprising data on visual function, retinal appearance and associated (extra-) ocular features. When possible, 
ERG, fundus pictures, autofluorescence (AF) images and optical coherence tomography (OCT) were obtained. In 
case of CEP290-related LCA, neurological (MRI) and nephrological data (kidney ultrasound [US], urinary and 
blood parameters) were evaluated. E1712  Coppieters et al. 
RESULTS 
Mutation screening strategy of known LCA genes 
As a first step, 102 probands were subjected to LCA chip analysis (91 LCA and 11 EORD). In total, 30 
sequence changes assigned as mutations by Asper Ophthalmics were identified in 47 individuals. Homozygous and 
compound heterozygous variants in one gene were each found in 13 patients; a single heterozygous variant was 
identified in 17 individuals. In addition, variants within two distinct genes were found in four patients. The 
zygosity of p.Glu1330X (CRB1) could not be determined in LCA-36. Confirmation of each mutation through 
direct sequencing identified two inconsistencies. At first, LCA-58 was genotyped heterozygously for the AIPL1 
mutation p.Trp278X by chip, while she was in fact homozygous. Secondly, a heterozygous p.Arg38AlafsX3 
mutation in AIPL1 (LCA chip version 2006) could not be confirmed in LCA-23. Instead, a heterozygous c.111C>T 
(p.=) variant was identified on the same nucleotide position. This miscall has previously been described 
(Henderson et al., 2007). In addition, subsequent sequencing of GUCY2D in LCA-51 revealed a heterozygous 
c.389del mutation that was not detected on the LCA chip. The variants c.2101C>T (p.Pro701Ser) (GUCY2D), 
c.3341A>G (p.Asp1114Gly) (RPGRIP1) (Vallespin et al., 2007a), c.286G>A p.Val96Ile (AIPL1) (Yzer et al., 
2006) and c.1301C>T (p.Ala434Val) (RPE65) (Morimura et al., 1998) have already been reported as 
polymorphisms and were therefore discarded as mutations. Moreover, identification of the GUCY2D p.Pro701Ser 
variant in a homozygous state in both healthy parents from an LCA patient further supported its non-pathogenic 
nature. After the exclusion of these polymorphisms, variants were assigned to be mutations in 45 patients (39 LCA 
and 6 EORD). 
Secondly, all patients with a heterozygous mutation identified through chip analysis were subjected to screening 
of the relevant gene. In addition, all patients with negative chip results underwent sequencing of 6 LCA genes. In 
the following sections, the molecular results are discussed in detail for each of the genes. 
 
CEP290 
CEP290 was found to be the most frequently mutated gene in our cohort, accounting for 30% (27/91) of cases 
with isolated LCA (Table 1). Since the LCA chip did not contain CEP290 variants at the onset of this study, only a 
fraction of currently known mutations were detected using this technique. The c.2991+1655A>G, c.4723A>T 
(p.Lys1575X) and c.3310-1_3310delinsAA mutations were the most recurrent, with gene-specific allele 
frequencies of 49%, 11% and 6%, respectively. Similar to previous studies, most of the mutations are either 
nonsense, frameshift or splice site mutations. Only two missense variants were identified, of which the pathogenic 
effect is currently uncertain (p.Ala1566Pro and p.Leu1694Pro) (Supp. Table S2). Overall, 13 novel CEP290 
mutations were identified to cause LCA. The complex allele c.3310-1_3310delinsAA has a predicted effect on 
splicing, which was confirmed by cDNA analysis (data not shown). The silent c.1824G>A change affects the last 
nucleotide of exon 18 and was also predicted to alter splicing (data not shown). 
Since  CEP290 mutations may cause a phenotypic spectrum ranging from isolated LCA to more complex 
disorders, we analysed 13 additional probands suffering from LCA-JS, SLS or CORS. CEP290 harbored mutations 
in seven of them (Table 1). Six probands carried known mutations, whereas a novel p.Thr2457AlafsX27 mutation 
segregated in family LCA-JS-2.  
Sequencing of the entire coding region did not reveal a second mutation in LCA-27, while the pathogenic effect 
of one variant was uncertain in LCA-25 and LCA-26. Subsequent cDNA screening in LCA-25 and LCA-27 was 
normal, thereby making deep intronic splice site mutations or large exon deletions/duplications very unlikely. No 
RNA was available for LCA-26. 
 
CRB1 
Mutations in CRB1 were found in 15 families with LCA (16%) and 5 families with EORD (Table 1). The LCA 
chip allowed the identification of a homozygous or compound heterozygous CRB1 mutation in 15 probands (12 
LCA and 3 EORD), and a heterozygous CRB1 mutation in 3 patients. Sequencing of the whole coding region of 
CRB1 in the latter revealed a known and novel mutation, respectively (LCA-29, p.Gln362X and LCA-34, c.4006-
1G>T), and a novel unclassified variant (EORD-3, p.Asp491Val) on the second allele (Supp. Table S2). Genetic Screening of LCA in Belgium  E1713 
 
Sequencing of the total coding region identified compound heterozygous mutations in two additional probands. In 
one of them, CRB1 screening was exceptionally performed without prior LCA chip analysis, given clear clinical 
indications for a CRB1-related phenotype (EORD-2). Indeed, this patient was compound heterozygous for the 
known p.Cys948Tyr mutation, and the novel p.Cys310Tyr variant, which is predicted to disrupt a disulfide bridge 
(Supp. Table S2). In addition, two sisters with LCA carried two novel frameshift mutations (LCA-41). As 
previously described, the p.Lys801X and p.Cys948Tyr mutations were most frequent, showing gene-specific allele 
frequencies in the LCA cohort of 27% and 23%, respectively. 
 
RPE65 
Eight cases with LCA showed mutations in RPE65 (9%) (Table 1). LCA chip analysis identified a homozygous 
RPE65 mutation in LCA-43 and LCA-47 and two compound heterozygous mutations in LCA-49. In addition, a 
heterozygous mutation was detected in four patients through LCA chip analysis. Sequencing of RPE65 in these 
individuals identified three novel mutations and the known p.Phe530LeufsX40 mutation which was not yet present 
on the LCA chip at the time (LCA-48). Although the evidence for a pathogenic nature of the novel mutation 
p.Trp331dup is not conclusive, segregation in patient LCA45a, her affected aunt LCA45b and her (healthy) 
parents sustains a causal role. The two other novel mutations result in a frameshift (LCA-46 and LCA-50). 
Following sequencing of the total coding region, one additional proband was found to be homozygous for the 
novel  RPE65 mutation p.Pro181Leu (LCA-44) (Supp. Table S2). Interestingly, segregation analysis of the 
mutations found in LCA-46 could only confirm segregation of p.Leu341Ser in the mother, suggesting that 
p.Ser121LeufsX6 occurred de novo (paternity confirmed). 
 
GUCY2D 
Mutations in GUCY2D were found in seven probands with LCA (8%) (Table 1). Five of them were identified 
with GUCY2D mutations using the LCA chip. One was homozygous for p.Phe565Ser (LCA-52), while three 
others carried p.Arg768Trp. One of the latter was homozygous (LCA-53); the other two were compound 
heterozygous for p.Phe565Ser (LCA-54) and the novel missense change p.Lys866Asn (LCA-55), respectively 
(Supp. Table S2). In addition, LCA-57 was heterozygous for the p.Pro575Leu variant that was previously 
identified in the mother of an LCA patient (Koenekoop et al., 2002). However, no second mutation was found. 
LCA-56 was compound heterozygous for the novel missense changes p.Glu196Val and p.Pro711Leu (Supp. Table 
S2). In addition, a novel splice site mutation was identified in LCA-51 (c.2577-2A>C). 
 
AIPL1 
Only two distinct AIPL1 variants were detected through LCA chip analysis in five LCA patients (5%) (Table 1). 
The p.Trp278X mutation occurred homozygously in four probands (LCA-58 to LCA-61). In addition, a 
heterozygous p.Thr114Ile variant was found in proband LCA-62. Direct sequencing of the AIPL1 gene identified 
the known variant p.Pro376Ser (missing signal on LCA chip). Segregation analysis in the parents, however, 
revealed a cis-allelic inheritance from the mother. No further mutations were detected following additional 
sequencing of AIPL1 in other patients. 
 
CRX 
LCA chip analysis identified 2 CRX missense variants in two LCA patients (Table 1). The p.Tyr142Cys variant 
was previously described as a mutation (Vallespin et al., 2007a). Stone and colleagues, however, considered this 
variant as a polymorphism based on the estimate of pathogenic probability and the identification of this variant in a 
patient with two disease-causing alleles in another LCA gene (Stone, 2007) (LCA-63). The pathogenicity of the 
second variant p.Val242Met also remains unclear (LCA-64) (Swain et al., 1997; Rivolta et al., 2001; Chen et al., 
2002). Given their uncertain pathogenic potential, both variants were discarded as mutations for further 
calculations. 
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RDH12 
Mutation screening of RDH12 was performed downstream of LCA chip results involving this gene. A 
heterozygous p.Ala269GlyfsX2 mutation was identified in two probands with EORD. Subsequent sequencing of 
RDH12 identified an additional missense change in both patients, p.Val233Asp (EORD-6) and p.Ser175Leu 
(EORD-7) respectively (Supp. Table S2). According to UniProt, the Ser175 residue might be a substrate binding 
site (http://www.uniprot.org/uniprot/Q96NR8). A known mutation located in the same codon, p.Ser175Pro, lacks 
the ability to catalyze the reduction of retinaldehyde to retinol in vitro (Lee et al., 2007). In addition, a 
homozygous p.Ala269GlyfsX2 mutation was identified in patient EORD-8, for which RDH12 sequencing was 
performed prior to LCA-chip analysis (upon request).  
 
RPGRIP1 
Similarly, screening of RPGRIP1 was performed in the context of LCA chip analysis. In one LCA patient, a 
heterozygous mutation was identified. Sequencing of RPGRIP1, however, did not identify a second mutation 
(LCA-65).  
 
Mutations in multiple LCA genes 
For the assessment of the potential involvement of a second gene in LCA, only variants with significant 
pathogenic potential were taken into account (see above). Two patients with CEP290-related LCA displayed a 
heterozygous mutation in another LCA gene: LCA-16 was heterozygous for the known p.Arg85Cys mutation in 
RPE65, while LCA-20 carried the common p.Lys801X mutation in CRB1. 
 
Identification of potential modifier alleles in the AHI1 gene 
The AHI1 gene was sequenced as a candidate modifier gene in eight patients with CEP290-related LCA who 
presented with mental retardation. Four of them were diagnosed with LCA (LCA-3, LCA-20, LCA-23 and LCA-
24); two patients also suffered from NPHP (SLS-2 and SLS-3) and in two other cases, the LCA phenotype was 
part of a JS diagnosis (CORS-1 and LCA-JS-3). A MTS was absent on brain imaging in two isolated patients with 
LCA (no data were available for LCA-20, LCA-24, SLS-2 and SLS-3).  
A heterozygous novel AHI1 p.Asn811Lys mutation was found in the most severely affected patient CORS-1, 
out of three patients with the same CEP290 genotype but different neurological involvement (SLS-2, SLS-3 and 
CORS-1). Moreover, AHI1 screening in the five remaining patients revealed a second heterozygous missense 
variant, p.His758Pro, in LCA-3. Conservation and in silico predictions for both changes suggest a possible effect 
on protein structure/function (Supp. Table S2). Interestingly, exonic splicing enhancer (ESE) predictions point to a 
change in ESEs for both variants (data not shown). Moreover, both changes are located in a conserved WD-40 
repeat (http://www.uniprot.org/uniprot/Q8N157) and were absent in > 340 Belgian control individuals.  
In addition, SLS-2 was found to be heterozygous for the known p.Ser1123Phe change. Although it concerns a 
potentially pathogenic variant that affects a phosphorylation site and is located in a highly conserved region 
(Dephoure et al., 2008), this change was considered a polymorphism because of its frequency in the Dutch 
population and the observation that it did not segregate in a family with JS (Valente et al., 2006a; Kroes et al., 
2008).  
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Table 1. Mutations identified in 80 unrelated patients with LCA/EORD, using LCA chip analysis and direct sequencing 
of CEP290, CRB1, RPE65, AIPL1, GUCY2D and CRX 
Patient Origin  Par 
cons  Segr 
Allele 1  Allele 2  Reference 
Intron/ 
exon 
Nucleotide 
change 
Amino acid 
change 
Intron/ 
exon 
Nucleotide 
change 
Amino acid 
change   
CEP290 
LCA-1 Belgium  - X  I26 c.2991+1655A>G*  p.Cys998X* I26  c.2991+1655A>G*  p.Cys998X*  (den Hollander et al., 
2006) 
LCA-2 Belgium  - X  I26 c.2991+1655A>G  p.Cys998X I26  c.2991+1655A>G  p.Cys998X  (den Hollander et al., 
2006) 
LCA-3
+ Belgium  -  X  I26  c.2991+1655A>G*  p.Cys998X*  E6 c.322C>T  p.Arg108X 
(den Hollander et al., 
2006) 
LCA-4 Belgium  - NA  I26 c.2991+1655A>G  p.Cys998X  E25 c.2695C>T  p.Gln899X 
(den Hollander et al., 
2006) 
LCA-5 Belgium  - NA  I26 c.2991+1655A>G  p.Cys998X  E34  c.4393C>T  p.Arg1465X 
(den Hollander et al., 
2006), (Brancati et al., 
2007) (CORS) 
LCA-6 Belgium  - X  I26 c.2991+1655A>G  p.Cys998X  E36  c.4723A>T  p.Lys1575X 
(den Hollander et al., 
2006), (Brancati et al., 
2007; Perrault et al., 
2007) 
LCA-7
F Belgium  -  NA  I26  c.2991+1655A>G  p.Cys998X E36  c.4723A>T p.Lys1575X 
(den Hollander et al., 
2006), (Brancati et al., 
2007; Perrault et al., 
2007) 
LCA-8 Belgium  - NA  I26 c.2991+1655A>G  p.Cys998X  E36  c.4723A>T  p.Lys1575X 
(den Hollander et al., 
2006), (Brancati et al., 
2007; Perrault et al., 
2007) 
LCA-9 Belgium  - X  I26 c.2991+1655A>G  p.Cys998X  E39 c.5344C>T  p.Arg1782X 
(den Hollander et al., 
2006) 
LCA-10 Lithuania  -  X  I26  c.2991+1655A>G  p.Cys998X  E6 c.384_385del  p.Asp128GlufsX17 
(den Hollander et al., 
2006) 
LCA-11 Belgium  -  X  I26  c.2991+1655A>G  p.Cys998X  E6 c.437del  p.Glu146GlyfsX17 
(den Hollander et al., 
2006) 
LCA-12 
The 
Netherlan
ds 
- NA  I26  c.2991+1655A>G*  p.Cys998X*  E19  c.1859_1862del  p.Arg621IlefsX2 
(den Hollander et al., 
2006), (Perrault et al., 
2007) 
LCA-13 Belgium  -  NA  I26  c.2991+1655A>G  p.Cys998X  E29 c.3422dup  p.Leu1141PhefsX5 
(den Hollander et al., 
2006) 
LCA-14  Belgium/ 
Morocco  - X  I26  c.2991+1655A>G*  p.Cys998X*  E31 c.4001del  p.Thr1334IlefsX2 
(den Hollander et al., 
2006) 
LCA-15 
(Perrault et 
al., 2007) 
Belgium -  NA  I26  c.2991+1655A>G  p.Cys998X E37  c.4962_4963del  p.Glu1656AsnfsX3 
(den Hollander et al., 
2006), (Perrault et al., 
2007) 
LCA-16
+  Belgium/ 
Greece  - X  I26  c.2991+1655A>G  p.Cys998X E40  c.5493del  p.Ala1832ProfsX19 
(den Hollander et al., 
2006), (Brancati et al., 
2007; Frank et al., 
2008) (CORS) 
LCA-17 Belgium  -  X  I26  c.2991+1655A>G  p.Cys998X  E40 c.5519_5537del  p.Lys1840ArgfsX5 
(den Hollander et al., 
2006) 
LCA-18 Belgium  -  X  I26  c.2991+1655A>G  p.Cys998X  E43  c.5865_5867delins
GG  p.Glu1956GlyfsX9 
(den Hollander et al., 
2006) 
LCA-19 Belgium  -  X  I26  c.2991+1655A>G  p.Cys998X  I13 c.1189+1G>A Splice  defect 
(den Hollander et al., 
2006) 
LCA-20
+ 
(Yzer et al., 
2006) 
Belgium -  NA  I26  c.2991+1655A>G  p.Cys998X  I21 c.2218-2A>C  Splice  defect  (den Hollander et al., 
2006) 
LCA-21 Belgium  -  X  I26  c.2991+1655A>G  p.Cys998X  I28-E29  c.3310-
1_3310delinsAA  Splice defect 
(den Hollander et al., 
2006) 
LCA-22 Belgium  -  NA  I26  c.2991+1655A>G  p.Cys998X  I28-E29  c.3310-
1_3310delinsAA  Splice defect 
(den Hollander et al., 
2006) 
LCA-23 Belgium  -  NA  I26  c.2991+1655A>G  p.Cys998X  I28-E29  c.3310-
1_3310delinsAA  Splice defect  (den Hollander et al., 
2006) 
LCA-24  Belgium  -  NA  E36  c.4723A>T  p.Lys1575X  E36  c.4723A>T  p.Lys1575X  (Perrault et al., 2007) E1716  Coppieters et al. 
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LCA-25
F Belgium  -  X E36  c.4723A>T  p.Lys1575X  E35 c.4696G>C  p.Ala1566Pro  UV  (Perrault et al., 2007) 
LCA-26  Belgium   X  E18  c.1824G>A  p.=, splice site  E38  c.5081T>C  p.Leu1694Pro UV   
LCA-27  Belgium -  NA  I26  c.2991+1655A>G  p.Cys998X  ?  ?  ?  (den Hollander et al., 
2006) 
SLS-1 Pakistan  FC  X  E2 c.21G>T  p.Trp7Cys  E2  c.21G>T  p.Trp7Cys  (Valente et al., 2006b) 
(CORS) 
SLS-2 Belgium  -  NA  E36  c.4723A>T  p.Lys1575X  E34  c.4393C>T  p.Arg1465X 
(Perrault et al., 2007), 
(Brancati et al., 2007) 
(CORS) 
SLS-3 Belgium  -  NA  E36  c.4723A>T  p.Lys1575X  E34  c.4393C>T  p.Arg1465X 
(Perrault et al., 2007), 
(Brancati et al., 2007) 
(CORS) 
CORS-1
+ 
(Brancati et 
al., 2007) 
Belgium SD  NA  E36  c.4723A>T  p.Lys1575X  E34  c.4393C>T  p.Arg1465X 
(Perrault et al., 2007), 
(Brancati et al., 2007) 
(CORS) 
LCA-JS-1 Belgium  -  X  I40  c.5587-1G>C  Splice  defect  E31  c.3793C>T  p.Gln1265X  (Perrault 2007), (Baala 
et al., 2007) (ML) 
LCA-JS-2 II-
1 
ND +  X 
E54 c.7366_7369del  p.Thr2457AlafsX27 E54  c.7366_7369del  p.Thr2457AlafsX27   
LCA-JS-2 II-
2  E54 c.7366_7369del  p.Thr2457AlafsX27 E54  c.7366_7369del  p.Thr2457AlafsX27   
LCA-JS-3 Belgium  -  NA  I28-E29  c.3310-
1_3310delinsAA  Splice defect  E54  c.7341dup  p.Leu2448ThrfsX8  (Sayer et al., 2006) 
CRB1 
LCA-28  Belgium -  NA  E7  c.2401A>T*  p.Lys801X*  E7  c.2401A>T*  p.Lys801X*  (den Hollander et al., 
2001) 
LCA-29 
(Yzer et al., 
2006) 
Belgium -  NA  E7  c.2401A>T*  p.Lys801X*  E5  c.1084C>T  p.Gln362X 
(den Hollander et al., 
2001), (Yzer et al., 
2006) 
LCA-30 
  Belgium -  X  E7  c.2401A>T*  p.Lys801X*  E7  c.2290C>T*  p.Arg764Cys* 
(den Hollander et al., 
2001), (Lotery et al., 
2001) 
LCA-31 
(Yzer et al., 
2006) 
Belgium -  X  E7  c.2401A>T*  p.Lys801X*  E8  c.2688T>A*  p.Cys896X* 
(den Hollander et al., 
2001), (Hanein et al., 
2004) 
LCA-32 
(Yzer et al., 
2006) 
Belgium -  NA  E7  c.2401A>T*  p.Lys801X*  E8  c.2688T>A*  p.Cys896X* 
(den Hollander et al., 
2001), (Hanein et al., 
2004) 
LCA-33  Belgium -  NA  E7  c.2401A>T*  p.Lys801X*  E9  c.2843G>A*  p.Cys948Tyr* 
(den Hollander et al., 
2001), (Lotery et al., 
2001) 
LCA-34  Belgium -  X  E7  c.2401A>T*  p.Lys801X*  I11 c.4006-1G>T  Splice  defect 
(den Hollander et al., 
2001) 
LCA-35  Belgium  +  NA  E9  c.2843G>A*  p.Cys948Tyr*  E9  c.2843G>A*  p.Cys948Tyr*  (Lotery et al., 2001) 
LCA-36 ND  -  NA  E9  c.2843G>A*  p.Cys948Tyr*  E11 c.3988G>T*  p.Glu1330X*  (Lotery et al., 2001), 
(LCA chip) 
LCA-37 Belgium  -  X  E9  c.2843G>A*  p.Cys948Tyr*  I8  c.2842+5G>A* Splice  defect* 
(Lotery et al., 2001), 
(den Hollander et al., 
1999) 
LCA-38 Belgium  -  X  E9  c.2843G>A*  p.Cys948Tyr*  I8  c.2842+5G>A* Splice  defect* 
(Lotery et al., 2001), 
(den Hollander et al., 
1999) 
LCA-39a 
Belgium -  X 
E9 c.2843G>A*  p.Cys948Tyr*  I8 c.2842+5G>A*  Splice  defect* 
(Lotery et al., 2001), 
(den Hollander et al., 
1999) 
LCA-39b  I11  c.4005+1G>A  Splice defect  I8  c.2842+5G>A  Splice defect 
(Hanein et al., 2004), 
(den Hollander et al., 
1999) 
LCA-40  Belgium -  NA  I11  c.4005+1G>A*  Splice  defect* I8  c.2842+5G>A*  Splice  defect* 
(Hanein et al., 2004), 
(den Hollander et al., 
1999) Genetic Screening of LCA in Belgium  E1717 
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LCA-41 II-1 
Belgium -  X 
E7 c.2441_2442del  p.Leu814ArgfsX23  E9  c.3713_3716dup  p.Cys1240ProfsX24   
LCA-41 II-2  E7 c.2441_2442del  p.Leu814ArgfsX23  E9  c.3713_3716dup  p.Cys1240ProfsX24   
LCA-42  ND +  NA  E11 c.3879G>A*  p.Trp1293X*  E11  c.3879G>A*  p.Trp1293X*  (Hanein et al., 2004) 
EORD-1 II-1 
Belgium -  X 
E9  c.2843G>A*  p.Cys948Tyr* E7 c.2401A>T*  p.Lys801X* 
(Lotery et al., 2001), 
(den Hollander et al., 
2001) 
EORD-1 II-2  E9 c.2843G>A  p.Cys948Tyr E7  c.2401A>T  p.Lys801X 
(Lotery et al., 2001), 
(den Hollander et al., 
2001) 
EORD-2 Belgium    NA  E9  c.2843G>A  p.Cys948Tyr  E4 c.929G>A  p.Cys310Tyr  (Lotery et al., 2001) 
EORD-3 Belgium  -  X  E9  c.2843G>A*  p.Cys948Tyr*  E6 c.1472A>T  p.Asp491Val  UV  (Lotery et al., 2001) 
EORD-4  Belgium    NA  E5  c.1084C>T*  p.Gln362X*  E5  c.1084C>T*  p.Gln362X*  (Yzer et al., 2006) 
EORD-5  Belgium  -  NA  E7  c.2290C>T*  p.Arg764Cys*  E7  c.2290C>T*  p.Arg764Cys*  (Lotery et al., 2001) 
RPE65 
LCA-43  Turkey FC  X  E3  c.131G>A*  p.Arg44Gln*  E3  c.131G>A*  p.Arg44Gln*  (Simovich et al., 2001)
LCA-44 Turkey  FC  X  E6 c.542C>T  p.Pro181Leu E6  c.542C>T  p.Pro181Leu   
LCA-45a 
Belgium -  X 
E7 c.700C>T*  p.Arg234X*  E9 c.991_993dup p.Trp331dup  (Marlhens et al., 1997)
LCA-45b  E9 c.991_993dup p.Trp331dup E9 c.991_993dup p.Trp331dup   
LCA-46  Portugal  
X 
(c.10
22T>
C) 
E10 c.1022T>C*  p.Leu341Ser*  E5 c.361delT  p.Ser121LeufsX6 
de novo 
(Morimura et al., 
1998) (ARRP) 
LCA-47  Belgium  -  X  E14  c.1590del*  p.Phe530LeufsX40* E14  c.1590del*  p.Phe530LeufsX40*  (Yzer et al., 2006) 
LCA-48  Belgium -  X  E14  c.1590del  p.Phe530LeufsX40 E5  c.370C>T*  p.Arg124X* 
(Yzer et al., 2006), 
(Morimura et al., 
1998) 
LCA-49  Belgium -  X  E14  c.1590del*  p.Phe530LeufsX40* I1  c.11+5G>A*  Splice  defect*  (Yzer et al., 2006), 
(Gu et al., 1997) 
LCA-50 
Belgium 
/Russia 
(mother) 
- X  E9 c.886dupA  p.Arg296LysfsX7  I1  c.11+5G>A*  Splice defect*  (Gu et al., 1997) 
GUCY2D 
LCA-51  Morocco/ 
Belgium  - NA  E2  c.389del  p.Pro130LeufsX36  I13 c.2577-2A>C  Splice  defect  (Perrault et al., 1996) 
LCA-52  Turkey  TC  NA  E8  c.1694T>C*  p.Phe565Ser*  E8  c.1694T>C*  p.Phe565Ser*  (Perrault et al., 1996) 
LCA-53  Belgium    NA  E12  c.2302C>T*  p.Arg768Trp*  E12  c.2302C>T*  p.Arg768Trp*  (Lotery et al., 2000) 
LCA-54  Morocco/ 
Belgium  - X  E12 c.2302C>T*  p.Arg768Trp* E8 c.1694T>C*  p.Phe565Ser*  (Lotery et al., 2000), 
(Perrault et al., 1996) 
LCA-55 Belgium  -  X  E12  c.2302C>T*  p.Arg768Trp*  E14 c.2598G>C  p.Lys866Asn  (Lotery et al., 2000) 
LCA-56  Belgium/ 
France  - X  E2  c.587A>T  p.Glu196Val UV  E11  c.2132C>T  p.Pro711Leu UV   
LCA-57  Africa -  NA  E8  c.1724C>T*  p.Pro575Leu*  UV  ?  ?  ?  (Koenekoop et al., 
2002) 
AIPL1 
LCA-58 
(Yzer et al., 
2006) 
Belgium -  X  E6  c.834G>A*  p.Trp278X*  E6  c.834G>A  p.Trp278X  (Sohocki et al., 2000a)
LCA-59 Belgium  -  NA  E6  c.834G>A*  p.Trp278X*  E6  c.834G>A*  p.Trp278X*  (Sohocki et al., 2000a)
LCA-60 Belgium    NA  E6  c.834G>A*  p.Trp278X*  E6  c.834G>A*  p.Trp278X*  (Sohocki et al., 2000a)
LCA-61 Belgium  -  X  E6  c.834G>A*  p.Trp278X*  E6  c.834G>A*  p.Trp278X*  (Sohocki et al., 2000a)
LCA-62 Africa  -  in cis  E3 
E6 
c.341C>T* 
c.1126C>T 
p.Thr114Ile* UV 
p.Pro376Ser UV  ?  ?  ?  (Sohocki et al., 2000b)
CRX 
LCA-63 Belgium  SC  NA  E4  c.425A>G*  p.Tyr142Cys*  UV  ?  ?  ?  (Vallespin et al., 
2007a) E1718  Coppieters et al. 
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LCA-64  Ruanda    NA  E3  c.724G>A*  p.Val242Met* UV  ?  ?  ?  (Swain et al., 1997) 
RDH12 
EORD-6  Belgium -  X  E6  c.806_810del*  p.Ala269GlyfsX2* E8  c.698T>A  p.Val233Asp 
(Janecke et al., 2004), 
https://www.carverlab.
org/carver-mutation-
database 
EORD-7 Belgium  +  X  E6  c.806_810del*  p.Ala269GlyfsX2*  E7 c.524C>T  p.Ser175Leu  (Janecke et al., 2004) 
EORD-8 Belgium      E6  c.806_810del  p.Ala269GlyfsX2  E6  c.806_810del  p.Ala269GlyfsX2  (Janecke et al., 2004) 
RPGRIP1 
LCA-65  Belgium      E16  c.2668C>T*  p.Arg890X*  ?  ?  ?  (Gerber et al., 2001) 
 
Novel mutations are indicated in bold. 
+: patients carrying a heterozygous mutation in an additional gene: LCA-3 (AHI1, 
c.2273A>C, p.His758Pro), LCA-16 (RPE65, c.253C>T, p.Arg85Cys) (Stone, 2007), LCA-20 (CRB1, c.2401A>T, p.Lys801X) 
(den Hollander et al., 2001) and CORS-1 (AHI1, c.2433T>G, p.Asn811Lys). *: identified through LCA chip analysis. 
F: LCA-7 
and LCA-25 are distantly related. X: segregation analysis performed and segregation confirmed. NA: no material available of 
family members. Reference: first publication describing the mutation in patients with LCA or EORD. In case of CEP290, these 
references may also refer to papers dealing with other phenotypes (phenotype mentioned between brackets). Seven patients 
were already described (corresponding reference is indicated in the first column). Abbreviations used: par cons: parental 
consanguinity; segr: segregation; FC: first cousins; SC: second cousins; TC: third cousins; SD: second degree; ND: no data; 
UV, unclassified variant; LCA, Leber Congenital Amaurosis; SLS, Senior-Loken syndrome; JS, joubert syndrome; ARRP, 
autosomal recessive retinitis pigmentosa; CORS, cerebello-oculo-renal syndrome; ML, Meckel-like syndrome. 
 
Clinical findings 
Extensive ophthalmological data (best corrected visual acuity [BCVA], refraction, ERG, visual fields, color 
vision testing, fundus aspect both with white light and autofluorescence imaging and the presence of nystagmus, 
night blindness, photophobia and additional features) as well as associated manifestations in patients with CRB1, 
RPE65, GUCY2D, AIPL1, CRX, RPGRIP1 and RDH12 mutations are summarized in detail in Supp. Table S3. In 
addition, Figure 1 depicts several representative fundi from patients with an established molecular diagnosis. An 
MTS due to midbrain abnormalities with cerebellar vermis aplasia was demonstrated in five patients with JS-
LCA/CORS and CEP290 mutations (Figure 2). 
Special attention was paid to the CEP290-related ocular phenotype, since this has been described in only a few 
LCA studies so far. It appeared that this phenotype displays only limited fundus alterations in the first few years of 
life. In a small subset of patients, no fundus abnormalities were obvious early on, while in the majority a 
marbleized fundus and/or salt and pepper aspect was seen during the first decade. This aspect further evolved from 
young adulthood into progressive outer retinal atrophy in the midperiphery with relative sparing of the central 
macula. Abnormalities of the central macula were absent in our patient cohort, despite the impression that 
CEP290-related disease is probably of a cone-rod type (based on ERG findings and the occurrence of 
photophobia). Of note is the presence of a hyperautofluorescent ring around the central macula on AF imaging, 
observed in four patients starting from the age of six (LCA-2, LCA-3, LCA-7 and LCA-25). Mild intraretinal 
spicular pigment migration occurred in three patients at an age between 7 and 33 years old (LCA-JS-1, LCA-6 and 
LCA-7). This aspect became even more pronounced at the age of 49 in patient LCA-7, where a predominant 
spicular pigmentation was mixed with less frequent intraretinal pigment migration with a nummular aspect. Visual 
acuity of this group was mostly limited to light perception. In the few patients with better preserved central vision, 
basic color vision was present and visual fields varied from severely concentrically constricted (LCA-8) to sparing 
of the central 30° at an age of 49 (LCA-7) (Supp. Table S3).  
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Figure 1. Clinical characteristics of eight LCA patients with an established molecular diagnosis, illustrating characteristic 
phenotypic features associated with different genotypes. CEP290. A & B: Early and later stage phenotype in right eye (RE) in 
LCA-3 at age 3 and 18 years respectively; note marbleized aspect of midperiphery at age 3, evolving towards atrophy later; 
macula stays well-preserved throughout evolution. C & D: Fundus and autofluorescence (AF) image of RE of LCA-25 at age 
eight years; note concentric hyperautofluorescent ring around macula suggesting a watershed zone between better and more 
affected retina with probably central area the better; midperipheral retina shows diffuse mottled hyperautofluorescence 
suggesting widespread outer retinal disease. E & F: Fundus image of RE and infrared image of left eye (LE) of LCA-7 at age 
33 and 49 years respectively; note pigment epithelium alterations in the mid- and far periphery of retina but no intraretinal 
pigmentation, and with fair preservation of macular area at age 33; at age 49 macula is still fairly well-preserved, but outer 
retinal atrophy and spicular intraretinal pigmentation is now prominent. CRB1.G: Fundus of RE of LCA-39a at age 16, showing 
typical yellowish discoloration of atrophic macula, surrounded by nummular type of intraretinal pigmentation; mild 
pseudopapilledema and prepapillary paravascular fibrosis also visible, as is peripheral greyish hue of outer retinal atrophy with 
fine white flecks and nummular pigmentation. GUCY2D. H & I: Fundus and AF image of RE of LCA-55 at age 9 years; fundus 
is essentially quite normal with only mild pigment epithelium alterations in the retinal periphery; however, AF image shows 
hyperautofluorescence in central macular area. RPE65. J: Fundus of LE of LCA-49 at age 10 who subsequently underwent 
gene therapy with AAV2-hRPE65v2 in RE (Maguire et al. 2009); apart from some discrete pigment epithelium alterations 
fundus is essentially normal; autofluorescence imaging could not be obtained due to lack of lipofuscin accumulation in retinal 
pigment epithelium (RPE) typical of this type of LCA. AIPL1. K & L: Fundus and AF image of RE of LCA-61 at age 19 years; 
central macular atrophy with yellowish hue is surrounded by area of better preserved peripheral macula; outer retinal atrophy 
with spicular intraretinal pigmentation visible in periphery; AF shows black area of atrophic central macula, but is typically not 
surrounded by hyperautofluorescent ring. RDH12. M & N: Fundus of EORD-7 at age 5 and 19 years respectively; note mild 
macular RPE changes which become more prominent with age; mild predominantly spicular intraretinal pigmentation also 
increases with age; however, preservation of patches of normal peripheral retina are most striking feature; these patches remain 
over time. 
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Figure 2. Magnetic resonance imaging (MRI) showing characteristic molar tooth sign (MTS) in five patients with Joubert 
syndrome/cerebello-oculo-renal syndrome due to mutations in CEP290 (all are axial sections through midbrain). Images 
organized from left to right; arrows indicate MTS of midbrain present in all due to midbrain malformation with hypoplastic 
cerebellar vermis and midline cleft (all images are T1 weighted except for panel D which is T2 weighted). A) CORS-1 at age 5 
years; B) LCA-JS-1 at age 7 years; C) LCA-JS-2 II-1 at age 14 years; D) LCA-JS-2 II-2 at age 17 years and E) LCA-JS-3 at 
age 2 years. 
 
 
DISCUSSION 
Genotypes of the Belgian LCA population 
In a cohort of 91 unrelated LCA patients, mainly originating from Belgium, a total of 61 different mutations 
(including 9 UVs) were found in 7 genes. Homozygous or compound heterozygous mutations were detected in 
65% (59/91) of probands, whereas only one heterozygous mutation could be identified in 4% (4/91) of probands. 
In addition to isolated LCA, this study also identified mutations in eight probands with EORD and seven probands 
with syndromic LCA (SLS, LCA-JS and CORS) (Table 1). 
LCA chip analysis proved to be a powerful initial tool as mutations were found in 41% (37/91) of patients with 
LCA. Subsequent sequencing of 6 genes (CEP290, CRB1, RPE65, GUCY2D, AIPL1 and CRX) enabled us to 
identify mutations in an additional 28% of cases. Of note, the majority of mutations found in the latter probands 
are now included in the LCA chip, increasing its detection rate to 65% if our cohort would have been analyzed 
using the latest version (v8, 641 variants). 
Segregation of disease alleles was demonstrated in 41 out of 43 families available, with two exceptions. The 
first one is LCA-62, in which the AIPL1 variants p.Thr114Ile and p.Pro376Ser were located in cis on the maternal 
chromosome. This finding challenges a previous study proposing this genotype as causal in an LCA patient 
(Sohocki et al., 2000b). In the second case, only one of two mutations identified in LCA-46 was found in the 
mother but not in father, suggesting that the other mutation arose de novo ( RPE65, p.Ser121LeufsX6, non-
paternity excluded) (Table 1). Of note, two different mutations in CEP290 were identified in CORS-1, originating 
from a consanguineous marriage, which illustrates that assuming homozygosity in offspring from a consanguinous 
mating can be a potential pitfall for the identification of the causal defect (Table 1).  
Our data demonstrate a key role for CEP290 in the Belgian LCA population, as CEP290 mutations were 
identified in 27 probands (30%). Although the prevalence of CEP290 mutations is not this high worldwide 
(Simonelli et al., 2007; Vallespin et al., 2007b; Seong et al., 2008; Li et al., 2009; Sundaresan et al., 2009), this 
study corroborates the importance of CEP290 in the Northwestern European population (den Hollander et al., 
2006; Perrault et al., 2007). The second most frequently mutated gene in our LCA population was CRB1 (16%), 
followed by RPE65 (9%), GUCY2D (8%) and AIPL1 (5%), which is in agreement with previous data (den 
Hollander et al., 2008). The RPGRIP1 gene – in this study only investigated with the LCA chip – accounted for 
less than 1% of the LCA population.  
In total, 30 novel mutations/variants were identified in this study (Table 1, Supp. Table S2). Interestingly, 5 out 
of 16 novel mutations in CEP290 are located nearby known changes: c.384_385del (c.384_387del, 
c.381_382delinsT) (Baala et al., 2007; Perrault et al., 2007), c.2218-2A>C (c.2218-4_2222del and c.2218-
15_2220del) (Sayer et al., 2006; Stone, 2007), c.3310-1_3310delinsAA (c.3310-1G>C) (Tory et al., 2007), Genetic Screening of LCA in Belgium  E1721 
 
c.5519_5537del (c.5515_5518del) (Sayer et al., 2006) and c.5865_5867delinsGG (c.5866G>T) (den Hollander et 
al., 2006). A similar observation was made for RDH12, in which the novel mutation p.Ser175Leu affects the same 
codon as the known mutation p.Ser175Pro (Perrault et al., 2004). Overall, these regions/codons might be more 
prone to mutational events. 
For several genes, a limited number of recurrent mutations made up the majority of mutated alleles. This was 
certainly the case for CEP290, in which c.2991+1655A>G was found in 89% of all LCA patients with CEP290-
related pathology. Together with p.Lys1575X and c.3310-1_3310delinsAA, a significant fraction of mutated 
alleles was identified in the LCA population (35/53 alleles). So far, p.Lys1575X has only been found in patients 
originating from northern France (Perrault et al., 2007) or Belgium (Brancati et al., 2007). This potential founder 
effect is supported by our study, since all patients who carry p.Lys1575X live in Flanders (northern part of 
Belgium). A similar regional prevalence was seen for p.Ala1832ProfsX19, which was inherited from the Greek 
father of LCA-16. The same mutation occurred in an Italian patient with CORS (Brancati et al., 2007) and in two 
consanguineous families of Kosovar-Albanian and Kosovar origin with MKS, sharing a common haplotype (Frank 
et al., 2008). For the other genes, the following mutations presented with a gene-specific allele-frequency of at 
least 20% in the LCA population: p.Lys801X (CRB1, 27%), p.Cys948Tyr (CRB1, 23%), p.Phe530LeufsX40 
(RPE65, 25%), p.Arg768Trp (GUCY2D, 31%), p.Phe565Ser (GUCY2D, 23%) and p.Trp278X (AIPL1, 89%). The 
presence of all but one of these mutations on the LCA chip significantly contributed to its high detection rate. 
In six LCA patients, only one mutation was found after sequencing of the gene apparently involved following 
chip testing. Notably, we might have failed to detect deep intronic and regulatory mutations or multi-exon 
deletions, as were recently demonstrated in CEP290 (Travaglini et al., 2009). In addition, it cannot be excluded 
that the phenotype is caused by mutations in a different gene, as was the case for LCA-20. Furthermore, new 
mutations in the other known genes cannot be ruled out here. Their contribution is expected to be limited however, 
taking into account the high detection rate obtained using the current strategy. Finally, these patients may carry 
mutations in as yet unknown genes.  
Phenotypes of the Belgian LCA population 
In addition, the phenotypes of patients with a molecular diagnosis were extensively studied. For all genes, 
nystagmus and hypermetropia were recurrent features. The oculodigital sign (plus enophthalmos) was often seen in 
all but RPE65-related LCA patients. A relatively higher incidence of both keratoconus and cataract was observed 
in the CRB1-related group, which may reflect secondary effects of a more severe retinal dystrophy compared to 
other genes. Indeed, several retinal abnormalities such as macular atrophy and intraretinal pigment migration 
already became apparent in the first decade of life in patients with CRB1-related disease, being earlier than 
generally seen for the other genes. In addition, a yellowish discoloration of the central macula was often observed. 
However, this feature is not entirely gene-specific, since it also occurred in a patient carrying RDH12 mutations 
(EORD-7). This feature may be due to more severe outer retinal atrophy in the macula in CRB1- and RDH12-
related disease, which may cause more intense scleral light reflection due to less absorption by the atrophic retinal 
pigment epithelium, with consequent highlighting of the macular luteal pigment. 
The RPE65-related phenotype proved to be typically associated with a fundus appearance which is essentially 
normal during first years and displays only later on fundus alterations which are initially mild. Visual acuity is 
generally somewhat better than that seen in CRB1-related LCA. However, it seems to be the relatively slow 
evolution of the phenotype which makes it particularly suitable for therapeutic intervention (Bainbridge et al., 
2008; Hauswirth et al., 2008; Maguire et al., 2008). For two patients from our cohort (LCA-47 and LCA-49), 
RPE65 gene-replacement therapy resulted in better visual function (Maguire et al., 2009). In addition, two patients 
with RPE65 mutations reported a period of increased visual function, possibly reflecting postnatal physiological 
cone maturation (LCA-44 and LCA-47) (Koenekoop et al., 2007). Hanein et al. classified both CRB1- and RPE65-
related LCA as rod-cone dystrophies because of a predominant occurrence of night blindness (Hanein et al., 2004). 
All RPE65-related phenotypes in this study correspond to this classification. In the CRB1-group, however, six 
patients with LCA and two with EORD also suffered from photophobia, even before the onset of night blindness in 
EORD-3.  
Similarly, the GUCY2D-related phenotype was found to have only limited fundus abnormalities. Although this 
phenotype was previously categorized as cone-rod dystrophy, one patient in our cohort had severe night blindness 
before photophobia became apparent (LCA-54).  E1722  Coppieters et al. 
In the patients with AIPL1 mutations, an RP-like phenotype emerged by their teenage years at the latest, and a 
maculopathy with (partial) outer retinal atrophy was typically present in the majority of cases (Dharmaraj et al., 
2004). 
A unique feature of RDH12-related early-onset dystrophy was the occurrence of areas with complete 
preservation of the chorioretina in the retinal periphery, alternating with regions of total atrophy (EORD-7).  
Notably, our study is one of the first reporting on the ocular phenotype of a larger group of LCA patients with 
CEP290 mutations (Supp. Table S3). In keeping with previously reported findings (Perrault et al., 2007), it 
appeared to be that of a severe cone-rod type retinal dystrophy. Visual acuity was mostly limited to light 
perception, as recently described (Walia et al., 2010). Interestingly, a limited subset of patients displayed no 
obvious retinal abnormalities in the first years of life. In general, the fundus contained either small white dots or, 
more frequently, a marbleized or salt and pepper aspect in the first to second decade. In two patients aged 18 and 
49, predominant spicular pigment migration was observed (LCA-6 and LCA-7), in contrast to the reported 
nummular pigmentation in one patient in the fourth decade (den Hollander et al., 2006). In one patient, nummular 
pigmentation was described in the first decade (LCA-10). Interestingly, a more severe phenotype was seen in 
LCA-20, who carried a heterozygous CRB1 null allele on top of two mutations in CEP290. 
 
Extra-ocular features of CEP290-related LCA and potential modifier alleles in AHI1  
Several patients with CEP290-related retinal dystrophy showed additional systemic features. Two patients with 
isolated LCA had several symptoms suggestive of renal dysfunction (LCA-3 and LCA-23, Supp. Table S3). LCA-
3 suffered from growth retardation, polydipsia, enuresis nocturna and diurnal incontinence. Kidney US at the age 
of seven, however, was normal. In LCA-23, kidney US at the age of three revealed increased echogenicity and 
kidneys without clear cortico-medullar differentiation. Despite this observation, no clinical nephrological 
manifestations were present at the age of 17. Since the age of onset of end-stage renal disease caused by CEP290 
mutations may exceed the age of 20 (Helou et al., 2007; Tory et al., 2007), a close nephrological follow-up of 
these patients is required. Interestingly, both of these patients carry the recurrent c.2991+1655A>G mutation, 
which so far has only been reported in LCA patients without any other associated pathology. Of note, kidney US 
was available for only a subset of patients, and in general performed very early in life, when developing kidney 
disease might be difficult to detect.  
In addition, four patients suffered from recurrent otitis media (OM) (LCA-5, SLS-1, SLS-3 and CORS-1, Supp. 
Table S3). Although this is common in childhood, it is worth mentioning that it is also a clinical manifestation 
often seen in primary ciliary dyskinesia (PCD), a genetically heterogeneous disorder of motile cilia (Leigh et al., 
2009). In a few cases, PCD with OM was associated with X-linked RP, caused by mutations in RPGR (Shu et al., 
2007). Notably, RPGR is a centrosomal protein that interacts with CEP290 (Chang et al., 2006). Moreover, loss-
of-function experiments of CEP290 in zebrafish caused developmental abnormalities of the otic cavity (Sayer et 
al., 2006). 
Strikingly, 33% of patients with CEP290-related isolated LCA presented with mental retardation and/or autism, 
in contrast to only 8% of patients with mutations in the other genes. Subtle brain abnormalities such as broadened 
lateral ventricles were seen on MRI in some patients. Of note, brain imaging was not available for a subset of 
patients. Additional neurological manifestations included movement abnormalities (LCA-21), and dyspraxia and 
balance/coordination problems (LCA-18), the latter of which was also evident in two patients with syndromic 
CEP290-related LCA (SLS-2 and CORS-1) (Supp. Table S3).  
Taken together, these extra-ocular manifestations fit well into the broad clinical spectrum of CEP290 mutations, 
varying from isolated LCA to the lethal MKS. In addition, the CEP290 allelic spectrum is highly complex. 
Mutations associated with isolated LCA in this study were previously reported in other ciliopathies (Table 1), 
albeit always in compound heterozygosity with a different mutation in the distinct phenotypes. Moreover, identical 
CEP290 genotypes can display interfamilial variable expressivity and intrafamilial variation of the neurological 
phenotype was observed in several families with CEP290-related pathology (Coppieters et al., 2010). The 
complexity of CEP290-related disease is further illustrated by two cases from this study.  
The first one is SLS-1, homozygous for p.Trp7Cys. Valente and coworkers identified the same mutation in 
patient with CORS, also of Pakistani origin (COR22, II:1). Despite a similar ocular and renal phenotype, both 
patients significantly differ in their neurological phenotype. A second and even more pronounced example is the 
variability in both nephrological and neurological involvement in three unrelated patients with the same Genetic Screening of LCA in Belgium  E1723 
 
p.Lys1575X/p.Arg1465X genotype (SLS-2, SLS-3 and CORS-1). Patients SLS-3 and CORS-1 displayed a similar 
clinical course of renal disease, with renal failure at the age of 16 and 14 years, respectively. In contrast, renal 
insufficiency in patient SLS-2 was not substantiated until the age of 30 (Supp. Table S3). Neurological signs of 
these three patients ranged from a mild mental handicap (SLS-2) over severe autism in combination with moderate 
mental retardation (SLS-3) to severe mental retardation associated with ataxia and a MTS (CORS-1). An MRI was 
not available for the other two patients, however.  
The AHI1 gene was screened as a candidate modifier gene in these three patients. Strikingly, CORS-1, with the 
most severe nephrologic and neurologic phenotype, carries a heterozygous novel p.Asn811Lys mutation in AHI1, 
which was absent in the two other patients. Upon screening of AHI1 in five additional patients with CEP290-
related disease and neurological involvement, a novel missense variant, p.His758Pro, was identified in LCA-3. 
Mutations in AHI1 encoding Jouberin are responsible for JS, with retinal involvement in 75% and renal 
involvement in less than 10% of all AHI1-associated patients (Kroes et al., 2008). Interestingly, both p.Asn811Lys 
and p.His758Pro affect conserved residues and are located in the predicted WD40-repeat, a domain conserved 
across all eukaryotes, mediating functions such as vesicular trafficking (Li and Roberts, 2001). Since AHI1 and 
CEP290 appear to be in the same pathway through their interaction with rab8a, mutations in one of both genes 
may modify a phenotype caused by the other (Kim et al., 2008; Tsang et al., 2008; Hsiao et al., 2009). Tory and 
colleagues already suggested a similar potential epistatic effect of CEP290 and AHI1 mutations on phenotypes 
related to NPHP1, encoding another interactor of AHI1 (Tory et al., 2007; Eley et al., 2008). Strikingly, one of the 
AHI1 variants they described as a potential modifier for neurological involvement in patients with NPHP1 
mutations, p.Arg830Trp, was recently identified as a modifier allele for retinal degeneration in patients with 
NPHP, independent of a primary NPHP1 mutation (Louie et al., 2010). Of note, four out of seven patients in the 
study from Tory and coworkers carrying p.Arg830Trp displayed visual impairment, with one blind individual 
(Tory et al., 2007). The p.Arg830Trp variant might affect AHI1 complex stability/formation (Louie et al., 2010). 
The variants identified here, assumed to represent a neurological modifier in patients with LCA, might disrupt 
interactions with other proteins, thereby influencing AHI1 function in other organ systems.  
Overall, a molecular diagnosis of CEP290 mutations might have considerable consequences towards the 
clinical prognosis of an individual. Given the potential involvement of ciliary modifiers and the presence of cilia 
throughout the whole body, the development of various additional clinical manifestations should be taken into 
account. As for LCA, both children and (young) adults should have a long-term close clinical neurological and 
nephrological follow-up, since some features have a later onset.  
In conclusion, molecular testing identified mutations in 69% of our LCA cohort, with a major involvement of 
CEP290. Detailed phenotyping of all patients with a molecular diagnosis revealed novel insights, mainly into the 
CEP290-related retinal phenotype, which is well documented for the first time in a larger patient group. The 
variable age-of-onset of the extra-ocular features emphasizes the importance of long-term clinical follow-up of 
LCA patients with CEP290 mutations. Moreover, the identification of potential modifiers of CEP290-related 
disease might contribute to a refined prognosis based on a molecular diagnosis. Finally, our findings fit with 
previous observations suggesting that the phenotype of ciliopathies is most likely determined by the synergistic 
effect of all variants occurring in the ciliary proteome. 
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SUPPORTING INFORMATION 
Supp. Table S1. Exon-flanking primers for the amplification of the human CEP290, CRB1, RPE65, GUCY2D, AIPL1, 
CRX, RDH12, RPGRIP1 and AHI1 genes and for the c.2991+1655A>G mutation in CEP290 
 
Gene  Exon  Forward primer (5’-3’)  Reverse primer (5’-3’) 
CEP290 
Exon 2  tttgtggcccaattgtctg  ccacctaagtaaacagaaaagcaac 
Exon 3  ccaaggtgcttaattggtca  tttcccctacacaccctttt 
Exon 4  tttactgaacgtctccatgtgc tggcagatccataaaataggag 
Exon 5  ttctagactcctattttatggatctgc ttcacaaccatatgctcagtcc 
Exon 6  atctgcactgaagtataatgc  tggtgatgacaaaatgaaca 
Exon 7  ggtgggagaattgcttgaac  acccgcatagacctgagatg 
Exon 8  ttggttctactgagccaaataatg  tctgaaggtaaccaaacacaaca 
Exon 9  ggtgaggctttaagtgtggtg  cttaatgaccaagacaggcaaa 
Exon 10  tggtcaatgccaattagtaaagg gtgaggtgattggagaaacaca 
Exon 11  ttccaggatgacttcaatgataaa aactcattgatgtgaaagaggtca 
Exon 12  cagagattatgccagtagttgctc ttgggaccaggtggtagaag 
Exon 13  aaaaggcatacttgtacccaca  tccatcatttacaaatgtaagcac 
Exon 14  aatggcataccacttttcttgc  tggcaaaaagtaaatgctcaaag 
Exon 15  gcatatgtacattttcctttagac  actccaaccccataaaatct 
Exon 16  tcacagaaagttacctcattcttc  cctctttcttgagccatttg 
Exon 17  tgtaggccttgaaccaaagac  ttcaggactgaacccactgac 
Exon 18  ggatcacgaggtcagaagat  aaatgagaagcttgtattggct 
Exon 19  gggattaagatcaccatctgc acagcaaggcaaatcaactg 
Exon 20  aactcaactattcacgttggattt  ttgaaagcagctcaagaaaaac 
Exon 21  tatcatgcttggcaatgaa  tcttataaggcacttattttccac 
Exon 22  ggcatttctaagcagaaactgaa  atctgcatgctttggtgatg E1730  Coppieters et al. 
Gene  Exon  Forward primer (5’-3’)  Reverse primer (5’-3’) 
Exon 23  tgtgttgcttacagatttggtga  caggataatcccaggcttaatg 
Exon 24  tgataactttgttgccttgcat tccgaatccatctgaagagc 
Exon 25  gatcaagtccaacaagatgc  cagaagaagcaattatgacaaa 
Exon 26  tgcatgtttttcttacatgg aaatgcaggcaaactttaat 
Intron 26  cattagaaagtcctaggcaagagacat
c  agtaaggaggatgtaagactggagatagag 
Exon 27  ggacacagccaaaccatatc  caggattattcatctgcctaagtt 
Exon 28  tccatggaactataatgctttc  tctgctttccttttaaacaattc 
Exon 29  tttaccctccttcagtctgttc ttaaccctgttaaaaccgatct 
Exon 30  gcaaacatgataacctctgatgg  ctgggcaacagaatgagacc 
Exon 31_1  agttccagctatgtttgcac ctcgtttggagggaagaaac 
Exon 31_2  ccaagggtaaagctccacta  ttgtagatctcatgtgccact 
Exon 32  caggagaatggcatgaacc  atcattatcatcaatggaggaatgt 
Exon 33  tcacctctctgagtttgtatt cagttgcagcattgagagtaa 
Exon 34  atcttgtttgttactctgtagcat  tggctattagaaacattataggag 
Exon 35_1  aagcatgcaaataactgctgtc accttgcttgcatgtttgc 
Exon 35_2  aatcaatgaactgaggcttcg  ggtgtaatccaatcacatgcaa 
Exon 36  gaggggacatgcataccagt  cggtgagctacaggaggaag 
Exon 37  tttgatcatttgaggaaccaaa ccagcagtcctgaggataaa 
Exon 38  gttgcagtcagccgagattg  actttttattacaacacggagat 
Exon 39  ttcaatgtggaaagaattgagtg tgtctagccaccaacagtgc 
Exon 40_1  tcctcaaggtagacttgacatgaa  ttgccttttcagttcatcattc 
Exon 40_2  ctactacctctatattgtaaatcagaca ttgtgggtgtttgttgaaga 
Exon 41  aaaatgcagaagcagctacca  ttcaatactgcttatagtcctcaa 
Exon 42  tcaacctgtatagcaaaatgaaca  cgagatcacaggaaaatcca Genetic Screening of LCA in Belgium  E1731 
 
Gene  Exon  Forward primer (5’-3’)  Reverse primer (5’-3’) 
Exon 43  tggattttcctgtgatctcg tcaattcacatgggaaaagaaa 
Exon 44  catttaaaggaggccttcagtg  tgagaaagatgtaatgcttttgg 
Exon 45  ggctttcaccagaacactcc  ggccttcaacaaataaatgct 
Exon 46  tgcatcaggcaataatgtgg cagatgcagaataaacactgaaa 
Exon 47_1  gctgcatgattttaggaatgtc  caatttttcattttcctgctca 
Exon 47_2  tggtagaagtggaaagacaatcc cccttagccttgcctctcat 
Exon 48  aacgttgggaacttcgttct tggtggaatgtgatgacagc 
Exon 49  aggaagaaaccaggttatcca  ttgaatacactgaatctatgagaaca 
Exon 50  ttgccaccactttttaatgc  ggggtgcccttcagttagat 
Exon 51  tgcttgtctctagttgtagca  ctaggacaatgccagttatgc 
Exon 52  cgtgaaggcttttgtattcca  aagacccaaagcttatcaggaa 
Exon 53  ggagggaggcagcattaagt  tgttaggaatagtcagatgaaca 
Exon 54  tgcctttattgctgtatttgacc  tcggagaactgcttatttcca 
CRB1 
Exon 1  atgaatccaatccagcctga  tgactgttcacattgactgg 
Exon 2_1  gttgaggcagcacaaaggtc  gctcctttctcctggggtg 
Exon 2_2  caatccctgtcaaggaagtg ggagtaaccatcaattccatc 
Exon 2_3  gagtgtgcttccagcccttg gagctaactacaccatctgtg 
Exon 3  ctctggtaaacaaagcattgtc  cagggagttctaagccaatc 
Exon 4  agtaagatgatgccatgggt  tcatttgctataagcgatatgtgt 
Exon 5  gacttagcagcttctctgaatt  gtcaagtcatatcccatctcc 
Exon 6_1  cctgagctattcatgcacttc  gaagtgagggatgcatgttcc 
Exon 6_2  gatattctcctgggctgtacc  gaagagccattggctgaacag 
Exon 6_3  ggctcagtttgtaacatagcc ggagtcgtcgattaaggtaag 
Exon 6_4  ccagcgatggagagtggca ctacaaacgaaggtgtggatg 
Exon 6_5  ggtgttgctctgcttaacttc  ctgctctgctctgaggcatg E1732  Coppieters et al. 
Gene  Exon  Forward primer (5’-3’)  Reverse primer (5’-3’) 
Exon 7_1  gtcttccatcccttctgtct  tttgggagagtttggagtca 
Exon 7_2  agatttggccaggatgactc aggccaccaatgtagatgac 
Exon 7_3  gactgaacttaatggtggattc ggtgggtcagtaacatcatc 
Exon 8  cagatatgtggtttcaccgtc  gtcgcaacttaactggtgag 
Exon 9_1  caatgatcattactattaataacgg gtgccatcattcactgactgc 
Exon 9_2  tcaattgcaaagtggcaaca ttaactgcaaacagccagtg 
Exon 9_3  caatataaagggcctgcaagg ctgcaactctgtcagagcag 
Exon 9_4  cactgtgaactcaacatcgatg cagtgatgcagagtatagcttc 
Exon 10  gaacaagatgaacagctgtgg  gctcagaattctcttccagaag 
Exon 11  ccaatgtattcaacagggacc  caactggctcgtcattcatac 
Exon 12  cctttgctatagaattcgcatc  gtacagtcatcacattcacag 
RPE65 
Exon 1  ctcaagactgcttccaaacc  tcccaaagccataactcctt 
Exon 2  ctatctctgcggactttgag  ggaagccagagaagagagac 
Exon 3  cccaaggcagggataagaag  ctaggccctactttgaggag 
Exon 4  ttgtcagtaacctctactcctc  atggccattctaagctcca 
Exon 5  ggcttgaaaattactggactg  ctgaacatcacctagcactg 
Exon 6  cctagggacaaaggtataatg  cacaatacagtaactttctcac 
Exon 7  gtatcaaaggtaggcaaagca  cgtttccaaatctgctgcta 
Exon 8  gtggcttgagaatcagccct  catcttcttcagaatcacaaac 
Exon 9  caagtttgtgattctgaagaag ccgtaatttccaggaacaatg 
Exon 10  cattgcctgtgctcatgtttg  cctgagagagatgaaacattc 
Exon 11  gaattctttcctgctcactgag  gagcacatgcttaggaaaactc 
Exon 12  caaagatgggttctgatggg cctcgtcaaggtgagatga 
Exon 13  acgaactaacatacagaactgc tcactttgttccagatagggt 
Exon 14  gacattcaatctatagcttggg  gcagacctgaagctgattttc Genetic Screening of LCA in Belgium  E1733 
 
Gene  Exon  Forward primer (5’-3’)  Reverse primer (5’-3’) 
GUCY2D 
Exon 2_1  catgggttactcgggcttg gagaagatggggtcgcaag 
Exon 2_2  atcatcccatgggttactcg  gcgatcccggcttctt 
Exon 2_3  tcgtgggtccggtgaa  gtagtggatcgtgtcgaagg 
Exon 3  ggacggcgccgcgagccaag  tcccctctcccttgccttct 
Exon 4  gtgggctgtgaccccgacc  tggtccatggcgattgtctc 
Exon 5  ctatcattcccagcctctcc  ttgctgcagacttccatttc 
Exon 6  gacggaacttggtgcccttgg  ggaaggaaccaaatttacgga 
Exon 7  ctcagcctgacctcaaccca  tcctcctgagagtgcgcctc 
Exon 8  gcattctgggacagtgagcc  agaaaccgatggccacctag 
Exon 9  ccccacattgccctgggcaga  cctgcccccaggacgtcacc 
Exon 10  agcaggctgaggctgcctct cccggtggatcctcgtctgc 
Exon 11  ctttctctgagatggctcct  tttagaggaaagagtgaggct 
Exon 12  caggccagggtcagaggcagc  ctcaggttgctgacaagcat 
Exon 13  cagctttaccagcttccttc  gcaggcagtgaggtcacctg 
Exon 14  gaccggctgcttacaca  gctggaggctggtgaag 
Exon 15  ggcaatcgcttcgtgtactc gatgggctggagcctgggaa 
Exon 16  ccccgaggccctacctaggt  acctccccgtcttgtccccg 
Exon 17  gcatctccacaggtccat agggtgagctgaggtttg 
Exon 18  caaacctcagctcaccctt  tctaagtcagaaagggatcgg 
Exon 19  gatgacgtgggccctgccctccc cttgggtgggacgttctgcag 
AIPL1 
Exon 1  gcacacctggaatgttgaa  aaaggtggatgggataggag 
Exon 2  gggccttgaacagtgtgtct  tttcccgaaacacagcagc 
Exon 3  agtgagggagcaggattc tgcccatgatgcccgctgtc 
Exon 4  ctcctgcccagggaga  gggagatgtgccacagg 
Exon 5  aaagtccaggaaggctatgg  taaggaacctgcagaccaag E1734  Coppieters et al. 
Gene  Exon  Forward primer (5’-3’)  Reverse primer (5’-3’) 
Exon 6  ctgggaagggagctgtag  aaaagtgacaccacgatcc 
CRX 
Exon 2  gtgcacgtcaccccatggtgagtaac cagaggtcctccaagagatgaggcc 
Exon 3  gtagaagggcagggaatgt  ctcctcccatcactctttgt 
Exon 4_1  gctggatgcaaagtagacag ccatgggagaaaggtaggg 
Exon 4_2  tctccgagctcctatttcag gatctaaactgcagggaagc 
RDH12 
Exon 3  ggagaggagcagagaagcag  gcttccagtgcaggtctttg 
Exon 4  tcttagtgtgagctcgtgaagg  ttctagtcagagcccccaag 
Exon 5  cccagtcccaagctcactta  tagtggggtggatgatggtt 
Exon 6  gggcaattatgcaggtctgt  ccctggacattctccacatt 
Exon 7  aattggttcacacccagaaga  tgacttcccaagttgctgtg 
Exon 8  tcctgagtccctccttctca  tcatcaggcacaaactcagc 
Exon 9  gggaccataaagatttccaga  ctttagggttggccttctcc 
RPGRIP1 
Exon 1  tgctgagaaattcctgctacaa tctgtgaaggccagcaagat 
Exon 2  tgagacatctaaagggttcaaaaa cagtctatcgacatgtttggc 
Exon 3  tgtactggggacagaaggcta aaacgtggctggcacatc 
Exon 4  cagcccttcatgttccagtt  ttccctgatcatgctgaaaa 
Exon 5  ccaaggttactgattcacttaatttc  cctctgagatggaggaaagg 
Exon 6  cgtgatgagaaatgggagaaa  cgagttgtgaggcttggatt 
Exon 7  agtgtgctaagtaacagtacct atttgctccagcaataggc 
Exon 8  caaagtcattctttgtgacatctg  ggagcttcgtttttgtcattt 
Exon 9  ggaaaatcctcattaatcccaat  attgagtaccaatttccccata 
Exon 10  aggtccaggagatgctgaaa  ggatcaagtgaggggattaaa 
Exon 11  ttttgttttcggagtgcaag  gttttctaatctcatcatcttccc 
Exon 12  agtttctgctgctggcattt ggacagccattgtgtgtttg 
Exon 13  gggtctgcaaggaaatcaaa  atgagaggcacccttcttga Genetic Screening of LCA in Belgium  E1735 
 
Gene  Exon  Forward primer (5’-3’)  Reverse primer (5’-3’) 
Exon 14  cacaacttggacttccacca  ggggaatacagatggtgtgg 
Exon 15  agcaccaatgcagaatttcc  gatgtagctcgctccaaagg 
Exon 16  gctcttcctcaccacagatcc  tctgctctgttgctcttgaca 
Exon 17  ggtgctgacaaatgctcact  cacatgacactcacagaggga 
Exon 18  tcccaaatccctttcttgtg  tgtctgcttctgcttctgct 
Exon 19  aaagaaggcaggaaggaagg  cttgaaagcctgatctcgtg 
Exon 20  tgaccagacagtggattgga  tgcattttccatcagcttca 
Exon 21  tgggttaattggatggcgta  attcaccccacaaaaatcca 
Exon 22  ccatgaataccactaatgaaagtct  catcagcacaaaaccaaactc 
Exon 23  aaatggaggcaagggaaaag  gggataagatttcaatccactttg 
Exon 24  cattcatttagcatccccagt  ggtactggagaaaaatgcctttag 
AHI1 
Exon 1_1  agggcactgtcatgatctcc  ggtaaacatgtcccgctgtg 
Exon 1_2  tcagtgccatcagaacagact ggctggactggcaacaatg 
Exon 1_3  cacagcgggacatgtttacc  ggcaggagaattgcttgacc 
Exon 1_4  ggaacattgttgccagtcca cgtggcctttgagttcagtt 
Exon 1_5  tctgggcatagcatcacaca  atgctaacaatgtttgagaggca 
Exon 2  tttgtccttgctgaccatgc  ggccctagatcaaagcctca 
Exon 3  tgggtgacacagcaagactc tggtcacatacctgaaagctga 
Exon 4  actttgggtccttgtcccat  agcaggtccctggtaaatgt 
Exon 5  aactgtgcatgaggcaggt  agcaaaccttgagacagcct 
Exon 6  agagaaatgaagcataatggcct acacatcttgcgctattgct 
Exon 7  tttgccctttaatgggatgtga tgacctatcatgtgtcctggt 
Exon 8  tggtgcattccagttctttgg  tgccatttgtttgggcaagt 
Exon 9  aggtgtggtcatctggttca cccatcccagtttacatggc 
Exon 10  aattgcggacacgaaagaca gaggagggtcagtggaatgt E1736  Coppieters et al. 
Gene  Exon  Forward primer (5’-3’)  Reverse primer (5’-3’) 
Exon 11  tgtgttagcctccattaaacgc  aaactccctgggctcttgg 
Exon 12  actgccagatgttccttggt cagccctaaactgacgttactc 
Exon 13  atgccacagtgcaaatggg  acacatgtactgagaggctcat 
Exon 14  gcccggccaccatattattc  ggttcattggctgtgttggt 
Exon 15  gcaccactggattctaccct  tgtgctgcaaatgtctttggt 
Exon 16  gctatcaactagccacattggac  tggcagtgatggctttagagt 
Exon 17  ggcctccagaactgtgagaa  ggtgaagaagcagaaacaaagga 
Exon 18  tcaactcctgctttaaatcaacctt  gttcagcgtgaaatctggca 
Exon 19  ggcatggctgtttgtgtctt  atggaccctccctaactgaatg 
Exon 20  cgtctcacttgattccacagc  tcatgttacccaggctggtc 
Exon 21  tgaggcagtagaatcgcttga  ggtttgctgttgtctggctt 
Exon 22  gagatcgtgccactgcattc  catttacttggcagcagggt 
Exon 23  ggcagatgcccttaaatgtc  tcttccactcttttggcaat 
Exon 24  agcacaatgaaggaaagcca tcatcttgtagcaccgaatgtt 
Exon 25  cctgtaggacagcactcaaga  acaggctaggcacaccttag 
Exon 26  ccttgtccatctgagtcccaa tcactgtgagtgtgctaccc 
Exon 27  ggaatgctaaacgcagcaca gctgatagcgtagtgaccga 
Exon 28  cgtcggtcactacgctatca  tttccctgcgctagctacaa 
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Supp. Table S2. In-silico predictions of the novel missense variants and known unclassified variants identified in this study using the Alamut software 
 
Gene  Nucleotide 
change 
Amino acid 
change 
Domain/ 
Region 
PolyPhen SIFT 
Grantham 
score 
Nucleotide 
conservation 
Amino acid 
conservation  Remarks 
Prediction 
PSIC 
score 
difference 
Prediction Score 
Median 
sequence 
conservation 
CEP290  c.5081T>C  p.Leu1694Pro 
UV  Coiled coil  Possibly 
damaging  1.995 
Affect 
protein 
function 
0.00* 3.44  98 
Weakly 
conserved 
(score: 0.0) 
Moderately 
conserved 
(considering 
12 species) 
 
CEP290  c.4696G>C  p.Ala1566Pro 
UV  Coiled coil  Possibly 
damaging  1.638 Tolerated  0.10  3.44  27 
Highly 
conserved 
(score: 1.0) 
Highly 
conserved, 
up to Frog 
(considering 
12 species) 
 
CRB1  c.929G>A p.Cys310Tyr 
EGF-like 8, 
extracellular 
domain 
Probably 
damaging  3.761 
Affect 
protein 
function 
0.00* 3.96  194 
Highly 
conserved 
(score: 1.0) 
Highly 
conserved, 
up to Cow 
(considering 
8 species) 
Disruption of 
annotated 
bond 
formation site 
(PolyPhen) 
CRB1  c.1472A>T  p.Asp491Val 
UV 
Laminin G-
like 1, 
extracellular 
domain 
Benign 1.410 
Affect 
protein 
function 
0.01* 3.96  152 
Highly 
conserved 
(score: 1.0) 
Weakly 
conserved 
(considering 
8 species) 
 
RPE65  c.253C>T p.Arg85Cys    Probably 
damaging  2.476 Tolerated  0.05  2.90  180 
Highly 
conserved 
(score: 1.0) 
Moderately 
conserved 
(considering 
18 species) 
 
RPE65  c.542C>T p.Pro181Leu    Probably 
damaging  2.956 
Affect 
protein 
function 
0.04 2.90  98 
Highly 
conserved 
(score: 1.0) 
Highly 
conserved, 
up to Fruitfly 
(considering 
18 species) 
Located next 
to metal ion 
binding site 
(UniProtKB) 
GUCY2D  c.587A>T  p.Glu196Val 
UV 
Extracellular 
domain 
Possibly 
damaging  1.650 
Affect 
protein 
function 
0.00* 4.32  121 
Weakly 
conserved 
(score: 0.3) 
Highly 
conserved, 
up to 
Opossum 
(considering 
10 species) 
 
GUCY2D  c.1724C>T  p.Pro575Leu 
UV 
Cytoplasmic 
domain  Benign 1.433 Affect 
protein  0.00* 4.32  98  Weakly 
conserved 
Highly 
conserved,  rs28743021 E1738  Coppieters et al. 
Gene  Nucleotide 
change 
Amino acid 
change 
Domain/ 
Region 
PolyPhen SIFT 
Grantham 
score 
Nucleotide 
conservation 
Amino acid 
conservation  Remarks 
Prediction 
PSIC 
score 
difference 
Prediction Score 
Median 
sequence 
conservation 
function  (score: 0.0)  up to 
Opossum 
(considering 
10 species) 
GUCY2D  c.2132C>T  p.Pro711Leu 
UV 
Protein 
kinase, 
Cytoplasmic 
domain 
Probably 
damaging  3.140 
Affect 
protein 
function 
0.00* 4.32  98 
Highly 
conserved 
(score: 1.0) 
Highly 
conserved, 
up to 
Opossum 
(considering 
10 species) 
 
GUCY2D  c.2598G>C p.Lys866Asn Cytoplasmic 
domain 
Probably 
damaging  2.236 
Affect 
protein 
function 
0.00* 4.32  94 
Highly 
conserved 
(score: 1.0) 
Highly 
conserved, 
up to 
Opossum 
(considering 
10 species) 
 
AIPL1  c.341C>T  p.Thr114Ile 
UV 
PPIase 
FKBP-type  Benign 0.179  Tolerated  0.13  3.34  89 
Weakly 
conserved 
(score: 0.0) 
Moderately 
conserved 
(considering 
12 species) 
rs8069375 
AIPL1  c.1126C>T  p.Pro376Ser 
UV   Benign  ?  Tolerated  0.48  4.32  74 
Weakly 
conserved 
(score: 0.0) 
Weakly 
conserved 
(considering 
12 species) 
 
CRX  c.425A>G  p.Tyr142Cys 
UV   Benign  1.458 
Affect 
protein 
function 
0.00* 4.32  194 
Highly 
conserved 
(score: 1.0) 
Highly 
conserved, 
up to Little 
brown bat 
(considering 
8 species) 
rs61748442 
CRX  c.724G>A  p.Val242Met 
UV   Benign  1.033  Tolerated  0.20  4.32  21 
Weakly 
conserved 
(score: 0.2) 
Highly 
conserved, 
up to Dog 
(considering 
8 species) 
RS61748459 
VAR_007949 
RDH12  c.524C>T p.Ser175Leu    Probably 
damaging 
Prediction 
basis: 
sequence 
annotation 
Affect 
protein 
function 
0.00* 3.61  145 
Weakly 
conserved 
(score: 0.2) 
Highly 
conserved, 
up to Fruitfly 
(considering 
15 species) 
Disruption of 
annotated 
binding site 
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Gene  Nucleotide 
change 
Amino acid 
change 
Domain/ 
Region 
PolyPhen SIFT 
Grantham 
score 
Nucleotide 
conservation 
Amino acid 
conservation  Remarks 
Prediction 
PSIC 
score 
difference 
Prediction Score 
Median 
sequence 
conservation 
RDH12  c.698T>A p.Val233Asp    Probably 
damaging  2.616 
Affect 
protein 
function 
0.00* 3.60  152 
Weakly 
conserved 
(score: 0.0) 
Highly 
conserved, 
up to Fruitfly 
(considering 
15 species) 
 
AHI1  c.2273A>C p.His758Pro  WD  4  Probably 
damaging  2.679 
Affect 
protein 
function 
0.03* 3.39  77 
Highly 
conserved 
(score: 1.0) 
Moderately 
conserved 
(considering 
12 species) 
 
AHI1  c.2433T>G p.Asn811Lys  WD  5  Possibly 
damaging  1.719 
Affect 
protein 
function 
0.00* 3.39  94 
Highly 
conserved 
(score: 1.0) 
Highly 
conserved, 
up to 
Tetraodon 
(considering 
12 species) 
 
AHI1  c.3368C>T p.Ser1123Phe    Probably 
damaging 
Prediction 
basis: 
sequence 
annotation 
Tolerated 0.07  3.67  155 
Highly 
conserved 
(score: 0.9) 
Weakly 
conserved 
(considering 
12 species) 
Disruption of 
annotated 
functional 
site (modified 
residue) 
(PolyPhen) 
 
Alamut provides for each variant the HGVS nomenclature and a nucleotide conservation score which was computed at UCSC from 17 vertebrates and has a range between 0 and 
1 (http://genome.ucsc.edu/cgi-bin/hgTrackUi?g=multiz17way). For missense variants, Alamut calculates the Grantham distance and automatically fills in queries for PolyPhen 
and SIFT prediction servers, based on the UniProt protein identifiers and FASTA sequences of several orthologs, respectively. In addition, information on topological as well as 
functional domains and variations (VAR) was extracted from the UniProtKB database using the following identifiers: O15078 (CEP290), P82279 (CRB1), Q16518 (RPE65), 
Q02846 (GUCY2D), Q9NZN9 (AIPL1), O43186 (CRX), Q96NR8 (RDH12) and Q8N157 (AHI1) (http://www.uniprot.org/uniprot/). Variants were designated as “unclassified 
variant (UV)” if no consensus was seen in all prediction programs used. *These substitutions may have been predicted to affect function just because the sequences used were not 
diverse enough. E1740  Coppieters et al. 
Supp. Table S3. Clinical data of 80 patients with mutation(s) in one of the LCA genes Part I 
 
Gene  Patient 
n
o  Gender  Night 
Blindness  Photophobia ERG  Color 
vision  Fundus aspect  Other features 
CEP290 
p.[Cys998X]+
[Cys998X] 
LCA-1 M      Absent 
(4mo)   
Optic disc pallor 
Retinal vessel attenuation 
Normal macula 
 
CEP290 
p.[Cys998X]+
[Cys998X] 
LCA-2 M    Mild  Absent 
(5mo & 1.5yrs)   
Pigmentary retinopathy 
Normal macula 
(6yrs) 
Retinal vessel attenuation 
Salt and pepper alterations 
Pseudopapilledema 
HyperAF ring around macula 
(14yrs) 
Eyepoking 
CEP290 
p.[Cys998X]+
[Arg108X] 
LCA-3 M  +  +  Absent 
(4mo) 
+ 
(6yrs) 
Normal optic discs 
Retinal vessel attenuation 
Normal peripheral retina 
Beginning of hyperAF around macula  
(6yrs) 
Eyepoking 
Enophthalmos 
CEP290 
p.[Cys998X(+
)Gln899X] 
LCA-4 F      Absent 
(2yrs)   
Retinal vessel attenuation 
Tapetal reflex of posterior pole 
Pseudopapilledema 
 
CEP290 
p.[Cys998X(+
)Arg1465X] 
LCA-5 M      Absent 
(4mo)     Eyepoking 
Enophthalmos 
CEP290 
p.[Cys998X]+
[Lys1575X] 
LCA-6 F  -  Strong 
(since 3.6yrs)
Severe CRD 
(3.3yrs) 
B/R and 
G/R 
Retinal vessel attenuation 
White marbleized changes 
Macular oedema 
(3.2yrs) 
Retinal vessel attenuation 
White marbleized around vascular arcade 
Discrete RPE alterations 
No macular reflex 
(4.9yrs) 
Extensive peripheral outer retinal atrophy  
Limited spicular intraretinal pigmentation  
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Gene  Patient 
n
o  Gender  Night 
Blindness  Photophobia ERG  Color 
vision  Fundus aspect  Other features 
Relative macular preservation 
Relatively darker perifoveal ring 
(18yrs)  
CEP290 
p.[Cys998X(+
)Lys1575X] 
LCA-7 M 
(+) 
(later in 
life) 
+ 
(early in life)
Subnormal 
(1yr) 
Absent 
(21yrs) 
+ 
(early in 
life) 
Peripheral salt and pepper intraretinal pigmentation  
Relative macular preservation 
(22yrs) 
Extensive midperipheral and peripheral outer retinal 
atrophy 
Limited spicular intraretinal pigmentation 
Relative macular preservation 
Development of synchysis scintillans 
(33yrs) 
More extensive intraretinal pigmentation (predominantly 
spicular) 
Relative macular preservation 
Hyper AF in central macula and mid- and far periphery 
Extensive confluent atrophy 
(49yrs) 
Eyepoking 
Enophthalmos 
Exotropia 
Posterior SCP 
cataract (star 
shaped) (49yrs) 
 
CEP290 
p.[Cys998X(+
)Lys1575X] 
LCA-8 F      Absent 
(16yrs)  R/G  Optic disc pallor   
CEP290 
p.[Cys998X]+
[Arg1782X] 
LCA-9 M    + 
Severe 
CRD 
(5mo & 1.2yrs) 
 Marbleized  retinal  changes   
CEP290 
p.[Cys998X]+
[Asp128Glufs
X17] 
LCA-10 F         
Nummular pigmentation 
Pseudopapilledema 
Maculopathy 
 
CEP290 
p.[Cys998X]+
[Glu146Glyfs
X17] 
LCA-11 M      Absent 
(6mo)    Optic disc pallor 
Yellow confluent peripheral spots 
Eyepoking 
Enophthalmos 
CEP290 
p.[Cys998X(+
)Arg621IlefsX
2] 
LCA-12 M      Absent   
Retinal vessel attenuation 
Peripheral pepper and salt alterations 
Macular RPE alterations 
(6mo) 
Enophthalmos 
CEP290  LCA-13 F      Absent    Optic disc pallor   E1742  Coppieters et al. 
Gene  Patient 
n
o  Gender  Night 
Blindness  Photophobia ERG  Color 
vision  Fundus aspect  Other features 
p.[Cys998X(+
)Leu1141Phef
sX5] 
(4mo) Retinal  vessel  attenuation 
CEP290 
p.[Cys998X]+
[Thr1334Ilefs
X2] 
LCA-14 F      Absent 
(5mo)   
Granular pigment alterations 
Normal macula 
(7mo) 
Eyepoking 
Enophthalmos 
Cataract 
CEP290 
p.[Cys998X(+
)Glu1656Asnf
sX3] 
LCA-15 
(Perrault, 
Delphin 
et al. 
2007) 
M   -  Absent   
Retinal vessel attenuation 
(7mo) 
Hyperaemic optic disc 
Marbleized, white spots 
Nummular pigmentation 
 (2yrs) 
Eyepoking 
Enophthalmos 
CEP290 
p.[Cys998X]+
[Ala1832Profs
X19] 
LCA-16 M      Absent 
(6mo & 10mo)   Yellow  spots  Eyepoking 
CEP290 
p.[Cys998X]+
[Lys1840Argf
sX5] 
LCA-17 M     
Absent 
(5mo) 
 
 
Full optic disc with no apparent excavation 
Marbleized fundus changes in the midperiphery 
Normal macula 
(8yrs) 
Eyepoking 
CEP290 
p.[Cys998X]+
[Glu1956Glyf
sX9] 
LCA-18 M    + 
(early in life)
Absent 
(3mo)   
Full optic discs  
Limited outer retinal atrophy 
Midperipheral salt and pepper alterations  
Normal macula 
(15yrs) 
Eyepoking 
Enophthalmos 
Keratoconus with 
acute hydrops 
(OD>OS) (13yrs) 
CEP290 
p.[Cys998X]+
[Splice 
defect] 
LCA-19 M  +  +  Absent 
(3mo)   
Very small optic disc excavation 
Retinal vessel attenuation 
Mild midperipheral salt and pepper alterations 
Bull’s eye maculopathy with preservation of central 
macula, surrounded by concentric area of more 
pronounced outer retinal atrophy  
(14yrs) 
Eyepoking 
Enophthalmos 
CEP290 
p.[Cys998X(+
)Splice 
defect] 
LCA-20 
(Yzer, 
Leroy et 
al. 2006) 
F -  -  Absent 
(9yrs)   
Optic disc pallor 
Retinal vessel attenuation 
RPE alterations 
maculopathy unknown 
Eyepoking 
Enophthalmos 
Cataract with lens 
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Gene  Patient 
n
o  Gender  Night 
Blindness  Photophobia ERG  Color 
vision  Fundus aspect  Other features 
(3mo) Keratoconus  (OD) 
Enucleation because 
of phacolytic 
glaucoma (OD) 
CEP290 
p.[Cys998X]+
[Splice 
defect] 
LCA-21 M  +    Absent    Optic disc pallor 
Retinal vessel attenuation   
CEP290 
p.[Cys998X(+
)Splice 
defect] 
LCA-22 M  -  -  Absent 
(4mo & 9mo)   
Normal optic discs  
White retinal spots 
Tapetal reflex 
 
CEP290 
p.[Cys998X(+
)Splice 
defect] 
LCA-23 F      Absent 
(5mo & 1.5yrs)   
Salt and pepper alterations  
Normal macula 
(5mo) 
Pinkish optic disc 
Mild retinal vessel attenuation 
RPE alterations (yellowish dots) 
(6yrs) 
Eyepoking 
Enophthalmos 
CEP290 
p.[Lys1575X(
+)Lys1575X] 
LCA-24 M             
CEP290 
p.[Lys1575X]
+[Ala1566Pro
] 
LCA-25 M  -  Strong 
Severe 
CRD 
(1.1yrs) 
 
No RPE alterations 
(4mo) 
Retinal vessel attenuation 
Discrete RPE alterations 
 (1.10yrs) 
Retinal vessel attenuation 
HyperAF ring around macula 
 (8yrs) 
Retinal vessel attenuation  
Salt and pepper alterations 
Mild macular pigment epithelial alterations 
(10yrs) 
Eyepoking 
Enophthalmos 
Exotropia 
CEP290 
p.[Leu1694Pr
o]+[=, splice 
LCA-26   -    Absent 
(4.5yrs)   
No retinal vessel attenuation 
No hyperpigmentation 
Midperipheral reticular aspect, especially around vascular 
Strabismus E1744  Coppieters et al. 
Gene  Patient 
n
o  Gender  Night 
Blindness  Photophobia ERG  Color 
vision  Fundus aspect  Other features 
site]  arcades 
Assymetric ectopia foveae OS>OD 
(3yrs) 
Normal optic disc 
Deep intraretinal white spots along vascular arcades 
HyperAF ring around macula 
No pigmentation/atrophy 
(5.4yrs) 
CEP290 
p.Cys998X  LCA-27  M     Subnormal 
(5mo & 1yr & 7yrs)  + 
Optic disc pallor 
No RPE alterations  
Normal macula 
 
CEP290 
p.[Trp7Cys]+[ 
Trp7Cys] 
SLS-1 F      Absent 
(2mo)   Abnormal  RPE   
CEP290 
p.[Lys1575X(
+)Arg1465X] 
SLS-2 F  +      + 
(12yrs)    Keratoconus 
Cataract 
CEP290 
p.[Lys1575X(
+)Arg1465X] 
SLS-3 M            Eyepoking 
CEP290 
p.[Lys1575X(
+)Arg1465X] 
CORS-1 
(Brancati
, Barrano 
et al. 
2007) 
F           Enophthalmos 
CEP290 
p.[Gln1265X]
+[Splice 
defect] 
LCA-JS-
1  M   -  Absent 
(first year of life)   
Optic disc pallor 
Salt and pepper alterations 
Mild spicular intraretinal pigmentation 
 
CEP290 
p.[Thr2457Al
afsX27]+[Thr
2457AlafsX27
] 
LCA-JS-
2 II-1  F +  +  Absent   
Normal optic discs 
Retinal vessel attenuation 
Salt and pepper alterations 
 
LCA-JS-
2 II-1  M   +  Absent       
CEP290 
p.[Leu2448Th
rfsX8(+)Splic
LCA-JS-
3  M   + 
Absent 
(4mo & 1.4yrs) 
 
  Optic disc pallor 
Retinal vessel attenuation   Genetic Screening of LCA in Belgium  E1745 
 
Gene  Patient 
n
o  Gender  Night 
Blindness  Photophobia ERG  Color 
vision  Fundus aspect  Other features 
e defect] 
CRB1 
p.[Lys801X(+
)Lys801X] 
LCA-28  M          Marbleized fundus changes   
CRB1 
p.[Lys801X(+
)Gln362X] 
LCA-29 
(Yzer, 
Leroy et 
al. 2006) 
M +  Mild  Absent 
(1yr & 30.6yrs) 
Basic 
Severe R-G 
and B-Y 
deficienty 
Optic disc pallor 
Retinal vessel attenuation 
Perivascular fibrosis 
No clear PPRPE 
Fine intraretinal white flecks 
Nummular intraretinal pigmentation 
Macular atrophy 
(30.6yrs) 
Eyepoking (mild) 
Enophthalmos 
(mild) 
Posterior 
subcapsular cataract 
(OS>OD) 
CRB1 
p.[Lys801X]+
[Arg764Cys] 
LCA-30  M            
CRB1 
p.[Lys801X]+
[Cys896X] 
LCA-31 
(Yzer, 
Leroy et 
al. 2006) 
M +  -  Absent 
(3mo)  Basic 
Retinal vessel attenuation 
Outer retinal atrophy 
RPE defects around vascular arcade 
Perimacular atrophic spots 
 (3mo) 
Normal optic discs 
Perivascular fibrosis 
No clear PPRPE 
Outer retinal atrophy 
Small white dots 
Nummular hyperpigmentation 
Pseudopapilledema 
Macular atrophy 
(8yrs) 
Eyepoking 
Enophthalmos 
Exotropia 
CRB1 
p.[Lys801X(+
)Cys896X] 
LCA-32 
(Yzer, 
Leroy et 
al. 2006) 
F + 
- 
(+ after 
keratoconus) 
  
Depigmentation around macula 
(15yrs) 
Macular aplasia: vessels of choroid become apparent 
(17yrs) 
Normal optic disc 
Retinal vessel attenuation 
Perivascular fibrosis 
No clear PPRPE 
Eyepoking 
Enophthalmos 
Esotropia 
Keratoconus with 
acute hydrops and 
rupture of Descemet 
membrane 
(20yrs) E1746  Coppieters et al. 
Gene  Patient 
n
o  Gender  Night 
Blindness  Photophobia ERG  Color 
vision  Fundus aspect  Other features 
Outer retinal atrophy 
White retinal spots 
Peripheral intraretinal pigment migration, predominant 
nummular 
Some midperipheral lipofuscin depositions 
Macular aplasia 
Pseudopapilledema 
 (33yrs) 
CRB1 
p.[Lys801X(+
)Cys948Tyr] 
LCA-33  F +    Absent 
(9mo & 1.7yrs)   
Pale and slightly swollen optic disc 
Diffuse outer retinal atrophy 
Small whitish deep intraretinal flecks  
Nummular intraretinal pigmentation 
Limited macular atrophy 
 
CRB1 
p.[Lys801X]+
[Splice 
defect] 
LCA-34  F   +  Absent 
(4mo & 1.5yrs)   
Retinal vessel attenuation 
Macular pigmentation 
Pseudopapilledema 
Eyepoking 
Strabismus 
CRB1 
p.[Cys948Tyr(
+)Cys948Tyr] 
LCA-35 F            Keratoconus  (OS) 
CRB1 
p.[Cys948Tyr(
+)Glu1330X] 
LCA-36 F         
Optic disc pallor 
Retinal vessel attenuation 
Nummular intraretinal pigmentation 
Macular alterations 
Coats reaction 
Enophthalmos 
Cataract 
Glaucoma 
(neovascular with 
OD seclusio pupillae 
and anterior 
synechiae) 
CRB1 
p.[Cys948Tyr]
+[Splice 
defect] 
LCA-37 M  +           
CRB1 
p.[Cys948Tyr]
+[Splice 
defect] 
LCA-38 M  +  -  Absent 
(9.1yrs) 
Basic 
(until 9yrs) 
Disturbed 
(after 9yrs) 
Optic disc pallor with irregular shape 
Retinal vessel attenuation 
Peripheral salt and pepper alterations 
(6yrs) 
Retinal vessel attenuation with tortuous aspect 
Extensive peripheral and macular outer retinal atrophy 
Eyepoking 
Enophthalmos 
Exotropia 
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Gene  Patient 
n
o  Gender  Night 
Blindness  Photophobia ERG  Color 
vision  Fundus aspect  Other features 
Small white deep intraretinal flecks 
Nummular intraretinal pigment migrations 
Yellowish hue of the macula 
6 astrocytoma-like retinal excrescences superior to right 
macula 
Pseudopapilledema with prominent sheathing of blood 
vessels near optic discs  
 (18yrs) 
CRB1 
p.[Cys948Tyr]
+[Splice 
defect] (LCA-
39a) 
and 
p.[Splice 
defect]+[Splic
e defect] 
(LCA-39b) 
LCA-39a  F +  +  Absent 
(4mo) 
Basic  
(early in 
life) 
Declining 
at the age 
of 12yrs 
Absent 
(15.11yrs) 
Optic disc pallor 
Retinal vessel attenuation 
Salt and pepper aspect 
Macular aplasia 
Total chorioretina atrophy in the central macula 
Pseudopapilledema 
Atrophic macular region with pigment near border 
(3yrs) 
Total atrophy of retina and choriocapillaris 
Midperipheral small white dots  
Midperipheral small nummular pigmentation 
Eyepoking 
Enophthalmos 
Esotropia 
LCA-39b M    +  Absent 
(8yrs & 16yrs)  - 
Optic disc pallor  
Small excavation optic disc (OD, not OS) 
Retinal vessel attenuation 
Extensive peripheral outer retinal atrophy 
Limited nummular intraretinal pigmentation 
Macular yellowish atrophy (OD>OS) 
(16yrs) 
 
CRB1 
p.[Splice 
defect(+)Splic
e defect] 
LCA-40  M +  -  Absent 
(2yrs)   
No optic disc excavation 
No perivascular sheathing 
Severe outer retinal and central macular atrophy 
Small deep intraretinal white flecks  
Extensive nummular intraretinal pigmentation 
 (11yrs) 
Cataract (OS>OD) 
Retinal detachment 
(OD: partial - 
inferior, OS: total) E1748  Coppieters et al. 
Gene  Patient 
n
o  Gender  Night 
Blindness  Photophobia ERG  Color 
vision  Fundus aspect  Other features 
CRB1 
p.[Leu814Arg
fsX23]+[Cys1
240ProfsX24] 
LCA-41 
II-1  F +  Mild  Absent 
(31yrs)  Disturbed 
Hyperaemic optic disc 
Retinal vessel attenuation 
Small pigment clumps scattered through retina 
Pseudopapilledema 
Normal macula 
(12yrs) 
Macular atrophy with pigment clumping 
(21yrs) 
Macular pseudocoloboma 
(23yrs) 
Limited perivascular sheathing around optic disc 
Extensive outer retinal atrophy  
Small white intraretinal flecks  
Pronounced nummular intraretinal pigmentation 
Central macular atrophy 
(36yrs) 
Eyepoking 
Enophthalmos 
Esotropia 
LCA-41 
II-2  F +  -  Absent 
(24yrs)  Disturbed  
Beginning macular atrophy with pigment alterations 
 (10yrs) 
Extensive peripheral outer retinal atrophy  
Extensive macular atrophy 
Extreme hyperpigmentation around central macula 
Pronounced peripapillary perivascular fibrosis 
Relative sparing of small retinal area just nasal to the 
optic disc (used for fixation) 
Pronounced mid and far-peripheral nummular intraretinal 
pigmentation  
(24yrs) 
Eyepoking 
Enophthalmos 
Esotropia 
SCP Cataract 
(complete, OS) 
CRB1 
p.[Trp1293X(
+)Trp1293X] 
LCA-42  F   +  Absent 
(2yrs)   
White retinal spots 
Salt and pepper pigmentation 
Maculopathy 
 (2yrs) 
Keratoconus 
Cataract (OD) 
CRB1 
p.[Cys948Tyr]
+[Lys801X] 
EORD-1 
II-1  F +  -  CRD   
Optic disc pallor 
Retinal vessel attenuation 
Salt and pepper alterations 
Nummular intraretinal pigmentation (over 360°) 
No maculopathy 
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Gene  Patient 
n
o  Gender  Night 
Blindness  Photophobia ERG  Color 
vision  Fundus aspect  Other features 
EORD-1 
II-2  M +  Mild  CRD   
Optic disc pallor 
Salt and pepper alterations 
No maculopathy 
 
CRB1 
p.[Cys948Tyr(
+)Cys310Tyr] 
EORD-2 M         
Optic disc pallor 
Peripheral nummular intraretinal pigmentation 
No maculopathy 
Cataract 
CRB1 
p.[Cys948Tyr]
+[Asp491Val] 
EORD-3 F 
+ 
(since the 
age of 5) 
Strong 
(since early 
age) 
Absent 
(4.10yrs)   
Hyperaemic optic disc 
Retina vessel attenuation 
Midperipheral pigment alterations 
Pseudopapilledema 
Bull’s maculopathy 
 (4yrs) 
 
CRB1 
p.[ Gln362X 
(+)Gln362X] 
EORD-4 M      Absent 
(5yrs)    Peripheral nummular intraretinal pigmentation 
No maculopathy  Cataract 
CRB1 
p.[Arg764Cys
(+)Arg764Cys
] 
EORD-5 F 
+ 
(since the 
age of 13-
14) 
-  Absent 
(12yrs) 
Normal 
(12yrs) 
Pseudopapilledema 
Maculopathy (edema) 
Coats reaction (OD) 
Mid-peripheral spicular intraretinal pigmentation 
Excavation optic disc (OS) 
SCP Cataract (OD) 
Glaucoma 
RPE65 
p.[Arg44Gln]
+[Arg44Gln] 
LCA-43  F 
Strong 
(since the 
age of 13-
14) 
- 
(searches for 
light) 
Absent 
(7mo & 2yrs) 
R/B (not 
R/Y) 
(4yrs) 
Discrete retinal vessel attenuation 
Normal fundus 
 Very small white intraretinal flecks in mid- and far 
periphery 
No preretinal fibrosis 
(4yrs) 
Esotropia 
RPE65 
p.[Pro181Leu
]+[Pro181Leu
] 
LCA-44 M  + 
- 
(searches for 
light) 
Absent 
(5mo & 4yrs)  Disturbed 
Retinal vessel attenuation 
Discrete RPE alterations 
(5mo) 
Optic disc pallor 
Retinal vessel attenuation 
Mild thinning of inferior retina 
Limited midperipheral intraretinal pigmentation  
Well-preserved macula 
 (7yrs) 
 
RPE65 
p.[Arg234X]+ LCA-45a F          Optic disc pallor 
Depigmentations and round hyperpigmentations   E1750  Coppieters et al. 
Gene  Patient 
n
o  Gender  Night 
Blindness  Photophobia ERG  Color 
vision  Fundus aspect  Other features 
[Trp331dup] 
(LCA-45a) 
and  
p.[Trp331dup
]+[Trp331du
p] (LCA-45b) 
LCA-45b              
RPE65 
p.Leu341Ser 
p.Ser121Leuf
sX6 (de novo) 
LCA-46  F        
Retinal vessel attenuation 
Limited but clear peripheral outer retinal atrophy  
No intraretinal pigmentation 
Relative preservation of essentially normal macula 
 (21yrs) 
 
RPE65 
p.[Phe530Leu
fsX40]+[Phe5
30LeufsX40] 
LCA-47  M + 
- 
(searches for 
light) 
Absent 
(9mo & 9yrs) 
G/B 
R/0/P 
Optic disc pallor 
Retinal vessel attenuation 
No pigmentation 
(5yrs) 
Normal optic discs 
Retinal vessel attenuation 
Discrete retinal thinning 
Cellophane maculopathy  
Limited macular pigment alterations 
Peripheral hypopigmentation 
Small discrete peripheral white flecks 
Total absence of AF 
(9yrs) 
Eyepoking 
Cataract (very 
limited posterior 
lens opacification) 
Semimydriasis 
(ODS) 
RPE65 
p.[Phe530Leu
fsX40]+[Arg1
24X] 
LCA-48  M     Absent 
(4mo & 1yr)  Basic 
Optic disc pallor 
Retinal vessel attenuation 
Outer retinal atrophy especially in inferior midperiphery 
Relative sparing of the macula.  
Mild preretinal macular fibrosis 
 
RPE65 
p.[Phe530Leu
fsX40]+[Splic
e defect] 
LCA-49  M Strong 
- 
(searches for 
light) 
Absent 
(1.9yrs)  Basic 
Retinal vessel attenuation 
No pigment alterations 
Normal macula 
 (1yr & 4.3yrs) 
Peripheral pigment alterations 
(6yrs) 
Normal optic disc  
Limited retinal vessel attenuation 
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Gene  Patient 
n
o  Gender  Night 
Blindness  Photophobia ERG  Color 
vision  Fundus aspect  Other features 
Peripheral RPE alterations without intraretinal pigment 
Very limited foveal pigment alterations 
RPE65 
p.[Arg296Lys
fsX7]+[Splice 
defect] 
LCA-50 F      Absent 
(5mo)   
Normal vessels  
Mild RPE alterations 
No hyperpigmentation 
Normal macula 
Esotropia 
Hypertropia 
GUCY2D 
p.[Pro130Leuf
sX36 
(+)Splice 
defect] 
LCA-51 M      Absent 
(11mo & 3yrs)   Normal  fundus  Eyepoking 
GUCY2D 
p.[Phe565Ser(
+)Phe565Ser] 
LCA-52 M      Absent 
(6mo)   Normal  fundus  Eyepoking 
Enophthalmos 
GUCY2D 
p.[Arg768Trp(
+)Arg768Trp] 
LCA-53 M             
GUCY2D 
p.[Arg768Trp]
+[Phe565Ser] 
LCA-54 F 
+ 
(since 
early age) 
+ 
(since the age 
of 2.6) 
Absent 
(3mo)    Normal fundus 
(1yr & 3.2yrs) 
Eyepoking 
Enophthalmos 
Esotropia 
GUCY2D 
p.[Arg768Trp]
+[Lys866Asn] 
LCA-55 M      Absent 
(4.4yrs)  - 
Pseudopapilledema 
Essentially normal fundus 
Limited peripheral salt and pepper alterations 
Limited hyperAF of the central macula 
(13yrs) 
Eyepoking 
GUCY2D 
p.[Glu196Val
]+[Pro711Leu
] 
LCA-56  F - Strong  Absent 
(3mo) 
Basic 
Strong R/G 
and B/Y 
defect 
Optic disc pallor 
Retinal vessel attenuation 
Limited peripheral outer retinal atrophy  
No intraretinal pigmentation 
Normal macula 
Foveolar yellowish atrophy 
No hyper- or hypoAF 
(25yrs) 
Eyepoking 
Enophthalmos 
Esotropia 
Keratoconus with 
acute hydrops 
(OD>OS) 
(16yrs) 
GUCY2D 
p.Pro575Leu  LCA-57  F +    Absent 
(3.3yrs) 
Severely 
disturbed 
Optic disc hypoplasia 
Bull’s maculopathy   
AIPL1 
p.[Trp278X]+
LCA-58 
(Yzer,  F   Mild  Absent 
(3mo & 1yr)    Bull's eye maculopathy, diffuse RPE alterations; limited 
intraretinal pigment migration of spicular type; sub- or   E1752  Coppieters et al. 
Gene  Patient 
n
o  Gender  Night 
Blindness  Photophobia ERG  Color 
vision  Fundus aspect  Other features 
[ Trp278X]  Leroy et 
al. 2006) 
deep intraretinal fine white deposits predominantly along 
vascular arcades 
AIPL1 
p.[Trp278X 
(+)Trp278X] 
LCA-59 M   
+ 
(since the age 
of 4.10) 
Absent 
(2yrs)   
Retinal vessel attenuation 
No intraretinal pigmentation 
Macular pigment alterations 
 (5yrs) 
Eyepoking 
AIPL1 
p.[Trp278X 
(+)Trp278X] 
LCA-60 M         
Normal optic discs 
Retinal vessel attenuation 
Peripheral outer retinal atrophy 
Spicular intraretinal pigmentation 
Total outer retinal aplasia of central macula, surrounded 
by thin rim of hyperplastic RPE 
(28yrs) 
 
AIPL1 
p.[Trp278X]+
[ Trp278X] 
LCA-61 F  + 
Strong 
(after first 
decade) 
Absent 
(3mo & 6mo)   
Limited optic disc pallor 
Retinal vessel attenuation 
Extensive outer retinal atrophy 
 Mid and far-peripheral spicular pigmentation  
Better preserved macula with central yellow atrophy 
(19yrs) 
Eyepoking 
Esotropia 
AIPL1 
p.[Thr114Ile; 
Pro376Ser] 
LCA-62 F      Absent 
(1.4yrs)    Optic disc pallor 
Retinal vessel attenuation  Eyepoking 
CRX 
p.Tyr142Cys  LCA-63 M      Absent 
(6mo)     Eyepoking 
CRX 
p.Val242Met  LCA-64 M             
RDH12 
p.[Ala269Glyf
sX2]+[Val233
Asp] 
EORD-6  M        
Optic disc pallor 
Retinal vessel attenuation 
Salt and pepper alterations 
 
RDH12 
p.[Ala269Glyf
sX2]+[Ser175
Leu] 
EORD-7 M 
+ 
(since 
early age) 
+  Absent 
(3.5yrs) 
Basic 
(5.10yrs) 
Limited retinal vessel attenuation 
Better preservation of the chorioretina in the posterior 
pole than in the periphery 
Clear retinal pigment epithelium alterations 
Peripheral areas of preserved chorioretina alternating with 
areas of total atrophy with predominant spicular 
intraretinal pigmentation 
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Gene  Patient 
n
o  Gender  Night 
Blindness  Photophobia ERG  Color 
vision  Fundus aspect  Other features 
(5yrs) 
Retinal vessel attenuation 
Yellowish discoloration of central macula 
More prominent spicular intraretinal pigmentation 
Areas with complete preservation of peripheral 
chorioretina 
(19yrs) 
RDH12 
p.[Ala269Glyf
sX2(+)Ala269
GlyfsX2] 
EORD-8              
RPGRIP1 
p.Arg890X  LCA-65     Strong         
 E1754  Coppieters et al. 
Supp. Table S3. Clinical data of 80 patients with mutation(s) in one of the LCA genes Part II 
 
 
Gene  Patient 
n
o  Gender Nyst 
BCVA  
(age) 
Refraction 
(age) 
VF MTS 
Neurologic
al 
Features 
Kidney  Other 
Features 
OD OS  OD  OS 
CEP290 
p.[Cys99
8X]+[Cys
998X] 
LCA-1  M    LP?  LP? +5 +5   Normal  MRI      
CEP290 
p.[Cys99
8X]+[Cys
998X] 
LCA-2 M  +  20/600 
(1yr & 5yrs) 
20/600 
(1yr & 5yrs) +7 +7     -     
CEP290 
p.[Cys99
8X]+[Arg
108X] 
LCA-3 M  +  2/24 
(6yrs) 
2/24 
(6yrs) 
+7 
(3mo) 
+8.25 
(6yrs) 
+7 
(3mo) 
+8.25 
(6yrs) 
 
MRI: 
Broadened 
supertentorial 
ventricular system 
without signs of 
intracranial 
hypertension 
(11mo) 
Mild MR  
Autism 
 
RDI 
Daytime 
incontine
nce 
Normal 
kidney 
US 
(6.10yrs)
Growth 
retardation 
(length and 
weigth) 
Prematurity 
(36w) 
CEP290 
p.[Cys99
8X(+)Gln
899X] 
LCA-4 F  +  NLP 
(since birth) 
NLP 
(since birth)         -     
CEP290 
p.[Cys99
8X(+)Arg
1465X] 
LCA-5 M    NLP 
(1.8yrs & 8yrs) 
NLP 
(1.8yrs & 
8yrs) 
+6 
(4mo) 
+6 
(4mo)   
TDM brains: 
modest cortical 
atrophy with 
limited subdural 
bifrontal fluid 
collection 
(4mo) 
EEG: normal 
(4mo) 
   MEI 
CEP290 
p.[Cys99
8X]+[Lys
1575X] 
LCA-6 F  + 
1.5/24 
(3.6yrs) 
1/20 
(18.5yrs) 
3/36 
(3.6yrs) 
2/10 
(18.5yrs) 
+4 
(18yrs) 
+4 
(18yrs)  Reduced
MRI: 
slightly 
broadened lateral 
ventricles (3.4yrs)
Learning 
disability 
Normal 
kidney 
US, 
normal 
kidney 
function 
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Gene  Patient 
n
o  Gender Nyst 
BCVA  
(age) 
Refraction 
(age) 
VF MTS 
Neurologic
al 
Features 
Kidney  Other 
Features 
OD OS  OD  OS 
(3yrs) 
CEP290 
p.[Cys99
8X(+)Lys
1575X] 
LCA-7 M  + 
CF at 2m 
(21yrs) 
LP with 
incomplete loc 
(49yrs) 
 
CF at 2m 
(21yrs) 
HM at 2m 
(49yrs) 
 
+3.5 
(42yrs) 
+3.5 
(42yrs) 
30° 
(35yrs & 
49yrs) 
 -     
CEP290 
p.[Cys99
8X(+)Lys
1575X] 
LCA-8 F  + 
1/60 
(6yrs) 
HM 2m 
(30yrs) 
1/36 
(6yrs) 
HM 1.5m 
(30yrs) 
+5 +5  5°    -     
CEP290 
p.[Cys99
8X]+[Arg
1782X] 
LCA-9 M  +  1/20 
(6yrs) 
1/20 
(6yrs)  +2.25 +2.25 10° 
(6yrs)  Normal MRI  -     
CEP290 
p.[Cys99
8X]+[Asp
128Glufs
X17] 
LCA-10 F  +  NLP  NLP  +4  +4    Normal MRI 
(10yrs)  - 
Normal 
kidney 
US 
(10yrs) 
Obesity 
CEP290 
p.[Cys99
8X]+[Glu
146Glyfs
X17] 
LCA-11 M  REM  NLP  NLP  +8  +8    Normal  MRI  -     
CEP290 
p.[Cys99
8X(+)Arg
621IlefsX
2] 
LCA-12 M  +  NLP  NLP  +10 
(6mo) 
+10 
(6mo)     - 
Normal 
kidney 
US (1yr) 
 
CEP290 
p.[Cys99
8X(+)Leu
1141Phef
sX5] 
LCA-13  F   NLP NLP  +8  +8   
Normal CT scan 
MRI: 2 atypical 
white matter 
lesions 
 (17yrs – 19yrs) 
MR 
Epilepsy     
CEP290 
p.[Cys99
8X]+[Thr
1334Ilefs
LCA-14 F  + 
LP? 
(7mo) 
NLP 
(7.8yrs) 
LP? 
(7mo) 
NLP 
(7.8yrs) 
    
MRI: slightly 
broadened lateral 
ventricles (5mo) 
-  
Limited 
ventricle 
septum 
defect E1756  Coppieters et al. 
Gene  Patient 
n
o  Gender Nyst 
BCVA  
(age) 
Refraction 
(age) 
VF MTS 
Neurologic
al 
Features 
Kidney  Other 
Features 
OD OS  OD  OS 
X2]  (VSD): slow 
closure, 
Asthma 
Familial 
palatoschisis 
Brother died 
from SIDS 
CEP290 
p.[Cys99
8X(+)Glu
1656Asnf
sX3] 
LCA-15 
(Perrault, 
Delphin 
et al. 
2007) 
M +  LP  LP 
Hypermetr
ia 
hypermetr
opic 
(strong) 
Hypermetr
ia 
hypermetr
opic 
(strong) 
  Normal MRI 
(1.3yrs) 
Dev del 
Autism?    Discrete 
scoliosis 
CEP290 
p.[Cys99
8X]+[Ala
1832Profs
X19] 
LCA-16 M  +  NLP  NLP  +8  +8      -    Obesitas 
CEP290 
p.[Cys99
8X]+[Lys
1840Argf
sX5] 
LCA-17 M  +  LP 
No loc 
LP 
No loc  +7 +7     Autism 
Normal IQ   
Carrier of a 
non-
pathogenic 
translocation
: 
45,XY,t(13;1
4) (father has 
the same) 
CEP290 
p.[Cys99
8X]+[Glu
1956Glyf
sX9] 
LCA-18 M  + 
LP 
No loc 
(early in life) 
LP 
No loc 
(early in 
life) 
   Conc 
constr 
Normal CT scan 
(5mo) 
Non-verbal 
learning 
disability 
Ataxia 
(Mild) 
Dyspraxia 
(10yrs) 
Balance 
and 
coordinatio
n problems
Normal 
kidney 
US 
(5mo) 
 
 
CEP290 
p.[Cys99
8X]+[Spli
LCA-19 M  +  NLP 
(since birth) 
NLP 
(since birth)      
MRI: Frontal and 
temporal cortical 
atrophy 
Autism 
Mild-
moderate 
Normal 
kidney 
US 
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Gene  Patient 
n
o  Gender Nyst 
BCVA  
(age) 
Refraction 
(age) 
VF MTS 
Neurologic
al 
Features 
Kidney  Other 
Features 
OD OS  OD  OS 
ce defect]  MR  
Verbal IQ 
= 55 
Coordinati
on 
problems 
(6mo) 
CEP290 
p.[Cys99
8X(+)Spli
ce defect] 
LCA-20 
(Yzer, 
Leroy et 
al. 2006) 
F + 
< 1/20  
(45yrs) 
NLP 
(54yrs) 
< 1/20  
(45yrs) 
NLP 
(54yrs) 
       Severe  MR   Meningitis 
(6w) 
CEP290 
p.[Cys99
8X]+[Spli
ce defect] 
LCA-21  M  +  LP  LP  +5  +5    Normal CT scan 
Mild MR 
ADHD 
Movement 
abnormaliti
es 
 
Chrom dupl 
14q24-32.3 
(< mother: 
carrier of a 
balanced 
translocation
) 
 
CEP290 
p.[Cys99
8X(+)Spli
ce defect] 
LCA-22 M  -  LP  LP          -     
CEP290 
p.[Cys99
8X(+)Spli
ce defect] 
LCA-23 F  +  LP?  LP?        - 
(1.2yrs) 
Severe MR
Dev Del 
Epilepsy 
Axial 
hypotonia 
(mild) 
Kidney 
US: 
hyperden
sity 
(3yrs) 
No other 
signs of 
NPHP 
(17yrs) 
Hyperlax 
ligaments 
Hyperlordosi
s 
 
CEP290 
p.[Lys157
5X(+)Lys
1575X] 
LCA-24 M                Severe  MR    
CEP290 
p.[Lys157
5X]+[Ala
1566Pro] 
LCA-25 M  + 
20/600 
(9mo) 
1/60 
(5yrs) 
20/600 
 (9mo) 
1/24 
(5yrs) 
+3.5 
(9yrs) 
+3.5 
(9yrs) 
10°- 15° 
paracent
ral 
Normal MRI 
(4mo)  -    E1758  Coppieters et al. 
Gene  Patient 
n
o  Gender Nyst 
BCVA  
(age) 
Refraction 
(age) 
VF MTS 
Neurologic
al 
Features 
Kidney  Other 
Features 
OD OS  OD  OS 
CEP290 
p.[Leu16
94Pro]+[
=, splice 
site] 
LCA-26   + 
5/60 
(3yrs) 
1/10 
(4.5yrs) 
5/60 
(3yrs) 
1/10 
(4.5yrs) 
+3.25 
(4.5yrs) 
+3 
(4.5yrs)          
CEP290 
p.Cys998
X 
LCA-27  M +  0.16  0.16      50°    -     
CEP290 
p.[Trp7C
ys]+[ 
Trp7Cys] 
SLS-1 F  + 
No reaction on 
light 
(2mo) 
No reaction 
on light 
(2mo) 
>+4 >+4    -? 
- 
No 
ataxia/hypo
tonia 
UTI 
RDI 
CKD5 
(5yrs) 
RTx 
(6yrs) 
Glue ear 
Clinodactyly 
Sibling died 
shortly after 
birth 
(enlarged 
kidneys, 
chrom 6 
defect) 
CEP290 
p.[Lys157
5X(+)Arg
1465X] 
SLS-2  F  +  LP with loc  LP with loc      <20° 
(14yrs) 
Broadened 4th 
ventricle 
Mild MR 
Balance 
problems 
Diagnosi
s renal 
insufficie
ncy 
(30yrs) 
RDI 
Peritonea
l dialysis 
(34yrs) 
Kidney 
transplan
t (34yrs) 
Syncopes 
Scoliosis 
 
CEP290 
p.[Lys157
5X(+)Arg
1465X] 
SLS-3 M    NLP  NLP         
Moderate 
MR 
Severe 
autism 
Mild ataxia
RDI 
(7yrs) 
Kidney 
US: 
hyperden
sity 
(13yrs) 
CKD5 
(16yrs) 
Peritonea
Recurrent 
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Gene  Patient 
n
o  Gender Nyst 
BCVA  
(age) 
Refraction 
(age) 
VF MTS 
Neurologic
al 
Features 
Kidney  Other 
Features 
OD OS  OD  OS 
l dialysis 
(since 
the age 
of 17) 
CEP290 
p.[Lys157
5X(+)Arg
1465X] 
CORS-1 
(Brancati, 
Barrano 
et al. 
2007) 
F  +  LP with loc  LP with loc  +10, +12  +10, +12    + 
Severe MR
Ataxia 
Balance 
problems 
RDI 
(6yrs) 
Kidney 
US: 
hyperden
sity 
(6yrs) 
CKD5 
(14yrs) 
Deceased 
(16yrs) 
Scoliosis 
Recurrent 
OM 
Congenital 
chylothorax 
Alternating 
tachypnea 
Syncopes 
CEP290 
p.[Gln126
5X]+[Spli
ce defect] 
LCA-JS-1 M  +  1/100  1/100  +5  +5  tubular  + 
(4yrs) 
Hypotonia 
Walking 
problems 
  
CEP290 
p.[Thr24
57AlafsX
27]+[Thr
2457Alaf
sX27] 
LCA-JS-2 
II-1  F +  1.5/10 1/10  +5  +5  10°  +  Walking 
problems    
LCA-JS-2 
II-2  A +  1/20  1/20  +4.5  +3.5  10°  + 
Mild MR 
Walking 
problems 
  
CEP290 
p.[Leu24
48ThrfsX
8(+)Splic
e defect] 
LCA-JS-3 M  REM  NLP 
(since birth) 
NLP 
(since birth)       + 
Severe 
psychomot
or 
retardation 
Hypotonia 
No ataxia 
Normal 
kidney 
US 
(1yr) 
Scoliosis 
CRB1 
p.[Lys801
X(+)Lys8
01X] 
LCA-28  M   1/100  1/100              
CRB1 
p.[Lys801
X(+)Gln3
62X] 
LCA-29 
(Yzer, 
Leroy et 
al. 2006) 
M + 
20/600 
(1yr) 
1/30 
(7.9yrs)  
20/600 
(1yr) 
<1/50 
(7.9yrs)  
+2.25 
(30.6yrs) 
(astigm) 
+1.88 
(30.6yrs) 
 (astigm) 
OD: 
central 
residual 
visual 
 -     E1760  Coppieters et al. 
Gene  Patient 
n
o  Gender Nyst 
BCVA  
(age) 
Refraction 
(age) 
VF MTS 
Neurologic
al 
Features 
Kidney  Other 
Features 
OD OS  OD  OS 
 1/40 
(25 yrs) 
1/40 
(25 yrs) 
field, 
OS: 
temporal 
inferior 
and 
partially 
superior 
visual 
field 
intact 
(30.6yrs
) 
CRB1 
p.[Lys801
X]+[Arg7
64Cys] 
LCA-30  M                    
CRB1 
p.[Lys801
X]+[Cys8
96X] 
LCA-31 
(Yzer, 
Leroy et 
al. 2006) 
M +  HM on 20 cm 
(3mo & 6yrs) 
HM on 20 
cm 
(3mo & 
6yrs) 
+10 +9.5      -     
CRB1 
p.[Lys801
X(+)Cys8
96X] 
LCA-32 
(Yzer, 
Leroy et 
al. 2006) 
F + 
1/100  
(1yr) 
 <1/600 
(35yrs) 
1/100  
(1yr) 
<1/600 
(35yrs) 
+4 
(19yrs) 
+4 
(19yrs) 
40°; 
remainin
g 
temporal 
crescent 
(19yrs) 
    
Asthma 
Torticollis 
(to the left) 
CRB1 
p.[Lys801
X(+)Cys9
48Tyr] 
LCA-33  F + 
CF at 1m 
(until 8yrs) 
HM at 0.5m 
(9yrs) 
CF at 1m 
(until 8yrs) 
CF at 10cm 
(9yrs) 
+4 +4  10°    -     
CRB1 
p.[Lys801
X]+[Splic
e defect] 
LCA-34  F + 20/800 
(1.11yrs) 
20/800 
(1.11yrs)  +5 +5 
Remaini
ng 
island in 
peripher
al field 
 -     
CRB1 
p.[Cys94
8Tyr(+)C
ys948Tyr
LCA-35 F    LP  LP               Genetic Screening of LCA in Belgium  E1761 
 
Gene  Patient 
n
o  Gender Nyst 
BCVA  
(age) 
Refraction 
(age) 
VF MTS 
Neurologic
al 
Features 
Kidney  Other 
Features 
OD OS  OD  OS 
] 
CRB1 
p.[Cys94
8Tyr(+)G
lu1330X] 
LCA-36 F  +  LP  LP          -     
CRB1 
p.[Cys94
8Tyr]+[S
plice 
defect] 
LCA-37 M  + 
LP 
(decreased 
since the age of 
13) 
LP 
(decreased 
since the age 
of 13) 
      Normal CT scan  -     
CRB1 
p.[Cys94
8Tyr]+[S
plice 
defect] 
LCA-38 M  + 
0.07 
LP with 
localisation 
(17yrs) 
0.07 
LP with 
localisation 
(17yrs) 
+9 +9  10°  Normal CT scan 
(5.9yrs)  -    
CRB1 
p.[Cys94
8Tyr]+[S
plice 
defect] 
(LCA-
39a) 
and 
p.[Splice 
defect]+[
Splice 
defect] 
(LCA-
39b) 
LCA-39a  F + 
1.5/36 
(4.9yrs) 
HM 1m 
(15.11yrs) 
2/36 
(4.9yrs) 
HM 1m 
(15.11yrs) 
+4.75 +5.25 10°    -     
LCA-39b  M   0.08  0.08     10°-20°   -     
CRB1 
p.[Splice 
defect(+)
Splice 
defect] 
LCA-40  M + 
0.08 
(3yrs) 
LP 
(22 yrs) 
0.08 
(3yrs) 
NLP 
(22 yrs) 
    <10°  Normal CT scan  -     
CRB1 
p.[Leu81
4ArgfsX2
3]+[Cys1
LCA-41 
II-1  F + 
3/10 
(8yrs) 
CF at 15cm 
(37yrs) 
3/10 
(8yrs) 
CF at 15cm 
(37yrs) 
+9 +9  30-50°    -     E1762  Coppieters et al. 
Gene  Patient 
n
o  Gender Nyst 
BCVA  
(age) 
Refraction 
(age) 
VF MTS 
Neurologic
al 
Features 
Kidney  Other 
Features 
OD OS  OD  OS 
240Profs
X24] 
LCA-41 
II-2  F + 
1/20 
(14yrs) 
1/20 
 (28yrs) 
1/100 
(14yrs) 
CF at 50cm  
(28yrs) 
+4.5 
Astigm 
 
+1.5 
Astigm 
 
50-60° 
horizont
ally 
70° 
verticall
y 
 -     
CRB1 
p.[Trp129
3X(+)Trp
1293X] 
LCA-42  F  
2/10 
(2yrs) 
LP 
4/10 
(2yrs) 
LP 
+5 +5  10°    -     
CRB1 
p.[Cys94
8Tyr]+[L
ys801X] 
EORD-1 
II-1  F -  1/50  1/50  +6  +6  60°    -     
EORD-1 
II-2  M   1/50  1/20  +3  +3  10°    -     
CRB1 
p.[Cys94
8Tyr(+)C
ys310Tyr
] 
EORD-2 M    LP  NLP  +  +  10°    -     
CRB1 
p.[Cys94
8Tyr]+[A
sp491Val 
t] 
EORD-3 F  + 
2/10 
(4yrs) 
1/20 
(11.9yrs) 
2/10 
(4yrs) 
1/20 
(11.9yrs) 
+4.5 
(10.10yrs)
+4.5 
(10.10yrs) 
Complet
e 
(4yrs) 
15°-30° 
(11yrs) 
MRI:  
subcortical white 
matter lesions, 
frontal (right) in 
centrum semi-
ovale 
Learning 
disability 
(but 
normal IQ)
  
CRB1 
p.[ 
Gln362X 
(+)Gln36
2X] 
EORD-4 M  + 
3/10 
(16yrs) 
LP 
3/10 
(16yrs) 
LP 
+6 +6  10°    -     
CRB1 
p.[Arg76
4Cys(+)A
rg764Cys
] 
EORD-5 F  - 
5/10 
(until 5yrs) 
LP no loc 
(18.4yrs ) 
7/10 
(until 5yrs) 
HM 
(18.4yrs ) 
+2D 
(12yrs) 
+5D 
+3D 
(12yrs) 
+5D 
30° 
(12yrs) 
Absent 
(19yrs) 
 - 
Normal 
kidney 
US 
 
RPE65 
p.[Arg44
Gln]+[Ar
g44Gln] 
LCA-43  F +  1/20  1/20  +4.5 
(7mo) 
+4.5 
(7mo) 
Conc 
constr  Normal MRI  MR 
Autism   Obesitas Genetic Screening of LCA in Belgium  E1763 
 
Gene  Patient 
n
o  Gender Nyst 
BCVA  
(age) 
Refraction 
(age) 
VF MTS 
Neurologic
al 
Features 
Kidney  Other 
Features 
OD OS  OD  OS 
RPE65 
p.[Pro18
1Leu]+[P
ro181Leu
] 
LCA-44 M  +  1/10 
(4yrs & 9yrs) 
3/10 
(4yrs & 
9yrs) 
-6 -6  
Normal CT scan 
and EEG 
(5mo) 
Behavioura
l anomalies
Normal 
kidney 
US 
(2yrs) 
 
Mild 
perceptive 
hearing loss 
(Cx26 
negative) 
 
RPE65 
p.[Arg23
4X]+[Trp
331dup] 
(LCA-
45a) and  
p.[Trp33
1dup]+[T
rp331du
p] (LCA-
45b) 
LCA-45a F    <1/20  <1/20               
LCA-45b                      
RPE65 
p.Leu341
Ser 
p.Ser121
LeufsX6 
(de novo) 
LCA-46  F                   
RPE65 
p.[Phe530
LeufsX40
]+[Phe53
0LeufsX4
0] 
LCA-47  M + 
1/10 
(5yrs) 
5/100 
(9yrs) 
1/10 
(5yrs) 
5/100 
(9yrs) 
+4 
(9yrs) 
+4.5 
(9yrs) 
Moderat
e conc 
constr 
 
Attention 
deficit 
disorder 
  
RPE65 
p.[Phe530
LeufsX40
]+[Arg12
4X] 
LCA-48  M + 
15/100 
(5yrs) 
2/10 
(10yrs) 
12/100 
(5yrs) 
2/10 
(10yrs) 
-2.25 -2.5 40°    -     
RPE65 
p.[Phe530
LeufsX40
]+[Splice 
defect] 
LCA-49  M 
+ 
(compensa
tory head 
movement
s) 
< 0.035 
(4.3yrs) 
1/60 
(10yrs) 
0.1 
(4.3yrs) 
1/20 
(10yrs) 
+1.5 
(20mo) 
+2.6 
(10yrs) 
+2.5 
(20mo) 
 +1 
(10yrs) 
Moderat
e conc 
constr 
Normal MRI 
(9mo)  -    E1764  Coppieters et al. 
Gene  Patient 
n
o  Gender Nyst 
BCVA  
(age) 
Refraction 
(age) 
VF MTS 
Neurologic
al 
Features 
Kidney  Other 
Features 
OD OS  OD  OS 
RPE65 
p.[Arg29
6LysfsX7
]+[Splice 
defect] 
LCA-50 F  +  1/10 
(3yrs) 
1/10 
(3yrs) 
+5 
(8mo) 
+5.75 
(8mo)    Normal MRI 
(7mo)      
GUCY2D 
p.[Pro130
LeufsX36 
(+)Splice 
defect] 
LCA-51 M  +  NLP  NLP               
GUCY2D 
p.[Phe565
Ser(+)Phe
565Ser] 
LCA-52 M  +  LP  LP  +4  +4    Normal  MRI  - 
US: 
hydro-
uretero-
nephrosis
 
GUCY2D 
p.[Arg76
8Trp(+)A
rg768Trp] 
LCA-53 M                     
GUCY2D 
p.[Arg76
8Trp]+[P
he565Ser] 
LCA-54 F  +  1/600 
(4.9yrs) 
1/120 
(4.9yrs) 
+3.75 
(4.7yrs) 
+4.25 
(4.7yrs) 
Constric
ted 
(2.6yrs) 
 -     
GUCY2D 
p.[Arg76
8Trp]+[L
ys866Asn
] 
LCA-55 M  +  LP  LP  +9  +9  10°    MR 
autism    
GUCY2D 
p.[Glu19
6Val]+[P
ro711Leu
] 
LCA-56  F + 
1/30 
(5.5yrs) 
3/100 
(23yrs) 
1/30 
(5.5yrs) 
3/100 
(23yrs) 
+6 +6 
Moderat
e conc 
constr 
 -     
GUCY2D 
p.Pro575
Leu 
LCA-57  F +  6/60  6/36 -6 -6   MRI: hypoplasia 
optic nerves  MR    
AIPL1 
p.[Trp278
X]+[ 
Trp278X] 
LCA-58 
(Yzer, 
Leroy et 
al. 2006) 
F  
<20/600 
(3yrs) 
1/50 
(8 yrs) 
<20/600 
(3yrs) 
1/50 
(8 yrs) 
+8  +8    Normal CT scan  -     Genetic Screening of LCA in Belgium  E1765 
 
Gene  Patient 
n
o  Gender Nyst 
BCVA  
(age) 
Refraction 
(age) 
VF MTS 
Neurologic
al 
Features 
Kidney  Other 
Features 
OD OS  OD  OS 
AIPL1 
p.[Trp278
X 
(+)Trp27
8X] 
LCA-59 M  + 
<1/50 
(2yrs) 
1/100 
(4.10yrs) 
<1/50 
(2yrs) 
1/100 
(4.10yrs) 
+3.5D 
(2.5yrs)  ?   Normal CT scan 
(6mo) 
Mild 
Developme
ntal delay 
  
AIPL1 
p.[Trp278
X 
(+)Trp27
8X] 
LCA-60 M                     
AIPL1 
p.[Trp278
X]+[ 
Trp278X] 
LCA-61 F  + 
<1/100 
(7yrs) 
LP with limited 
loc 
(21yrs) 
<1/100 
(7yrs) 
LP with 
limited loc 
(21yrs) 
+6 +6 
20° 
(7yrs) 
Residual 
pericentr
al 
remnant
s 
(21yrs) 
Normal CT scan 
(10mo)  -    
AIPL1 
p.[Thr114
Ile; 
Pro376Se
r] 
LCA-62 F  +  1/10  1/10        Normal  MRI  -     
CRX 
p.Tyr142
Cys 
LCA-63 M  +  LP  LP  +9  +9      -     
CRX 
p.Val242
Met 
LCA-64 M                     
RDH12 
p.[Ala269
GlyfsX2]
+[Val233
Asp] 
EORD-6  M - 
5/10 
(4yrs) 
1/10 
(23yrs) 
5/10 
(4yrs) 
1/10 
(23yrs) 
  
30° 
(8yrs) 
5° 
(12yrs) 
Normal CT scan  -     
RDH12 
p.[Ala269
GlyfsX2]
+[Ser175
Leu] 
EORD-7 M  + 
3/9 
(3.5yrs) 
HM 
(19yrs) 
3/9 
(3.5yrs) 
1.5/10 
(19yrs) 
  
OD: 
temporal 
crescent, 
OS: 70° 
(6yrs) 
 -     E1766  Coppieters et al. 
Gene  Patient 
n
o  Gender Nyst 
BCVA  
(age) 
Refraction 
(age) 
VF MTS 
Neurologic
al 
Features 
Kidney  Other 
Features 
OD OS  OD  OS 
OD: 
status-
quo 
OS: 
central 
5° 
(19.3yrs
) 
RDH12 
p.[Ala269
GlyfsX2(
+)Ala269
GlyfsX2] 
EORD-8 M    4/10  4/10      10°         
RPGRIP1 
p.Arg890
X 
LCA-65 M    1/10  1/10      10°         
 
If available, the age of the first and last measurement is mentioned between brackets. A question mark indicates an uncertain status. Blank fields indicate features for which no 
information could be obtained. Clinical data on the two patients included in the Phase I clinical trial for RPE65 gene-replacement therapy (LCA-47 and LCA-49) concern the 
period preceding therapy. Characteristics described in “Other features” are binocular, if not mentioned otherwise.  
Abbreviations used: N
o, number;; nyst, nystagmus; BCVA, best corrected visual acuity; OD, right eye; OS, left eye; ODS, both eyes; ERG, electroretinogram; VF, visual 
field; MTS, molar tooth sign; MRI, magnetic resonance imaging; MR, mental retardation; NPHP, nephronophtisis; SE, spherical equivalent; +, present; -, absent; yr(s), year(s); 
mo, month(s); W, week(s); REM, roving eye movements; HM, hand motion; LP, light perception; NLP, no light perception; CF, counting fingers; AF, autofluorescence; OCT, 
optical coherence tomography; US, ultrasound; SIDS, sudden infant death syndrome; conc constr, concentrically constricted; G, green; B, blue; R, red; O, orange; P, pink; RPE, 
retinal pigment epithelium; PPRPE, preserved para-arteriolar retinal pigment epithelium; astigm, astigmatism; loc, localization; CRD, cone-rod dystrophy; SCP, subcapsularis 
posterior; dev del, developmental delay; MEI, middle ear infections; RDI, renal diabetes insipidus; CKD5, renal failure; RTx, transplantation. 
 